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Background: Over 4 billion people worldwide are exposed to dietary aflatoxins, which can 
cause liver cancer (hepatocellular carcinoma, HCC) in humans independently and interact with 
chronic hepatitis B virus (HBV) infection to increase the cancer risk. However, the global burden 
of HCC from aflatoxin exposure remains unclear. 
 
Objectives: We sought to determine 1) the global burden of HCC attributable to aflatoxin 
exposure; 2) the population-attributable risk (PAR) of HCC from aflatoxin in high exposure 
areas; 3) the quantitative model of effects between aflatoxin exposure and HBV infection in 
increasing liver cancer risk. 
 
Methods: We first conducted a quantitative cancer risk assessment, for which we collected 
global data on foodborne aflatoxin levels, consumption of aflatoxin-contaminated foods, and 
HBV prevalence.  Aflatoxin’s cancer potencies for HBV+ and HBV- individuals, and uncertainty 
in all variables, were considered in calculating the global burden of aflatoxin-related HCC. Then, 
we conducted a meta-analysis on the eligible studies identified by literature search. Summary 
odds ratios (ORs) of aflatoxin-related HCC with 95% confidence intervals were calculated in 
HBV+ and HBV- individuals, as well as the general population. We calculated the PAR of 
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aflatoxin-related HCC for each study as well as the combined studies, accounting for HBV 
status. 
 
Results: 25,200-155,000 HCC cases worldwide may be attributable to aflatoxin exposure. Most 
cases occur in sub-Saharan Africa, Southeast Asia, and China, where populations suffer from 
both high HBV prevalence and largely uncontrolled dietary aflatoxin. In these areas, the PAR of 
aflatoxin-related HCC with 95% CI was estimated at 17% (14-19%) for overall population, and 
higher in HBV+ (21%) than HBV- (8.8%) populations. If the one study that contributed most to 
heterogeneity in the analysis is excluded, the summarized OR of HCC with 95% CI is 73.0 
(36.0-148.3) from the combined effects of aflatoxin and HBV, 11.3 (6.75-18.9) from HBV only, 
and 6.37 (3.74-10.86) from aflatoxin only. The PAR of aflatoxin-related HCC increases to 23% 
(21-24%).  
 
Public Health Significance: Aflatoxin may play a causative role in 4.6-28.2% of all global HCC 
cases. In high exposure areas, aflatoxin exposure may multiplicatively interact with HBV to 
induce HCC and attribute to 14-19% of liver cancer cases. 
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1.0  INTRODUCTION 
Aflatoxins are secondary metabolites produced primarily by the fungi Aspergillus flavus 
and A. parasiticus, which can infect crops such as maize, peanuts, cottonseed, and tree nuts. 
Aflatoxins contaminate the diets of a large proportion of the world’s population. Exposures are 
highest in tropical and sub-tropical regions where the fungus is prevalent, maize and peanuts are 
staples in the diet, and food storage conditions are sub-optimal 1,2.  
Aflatoxin is one of the most potent naturally occurring human hepatocarcinogens known.  
The International Agency for Research on Cancer (IARC) has classified “naturally occurring 
mixes of aflatoxins” as a Group 1 known human carcinogen 3. Abundant epidemiological 
evidences suggest that high aflatoxin exposure interacts with chronic hepatitis B virus (HBV) 
infection to increase liver cancer (hepatocellular carcinoma, HCC) risk in individuals with both 
risk factors 4-8. More recently, toxicological models for the mechanism of the synergism of these 
two risk factors have emerged 9-11, and are summarized in Wild and Gong 12.  Unfortunately, 
both high aflatoxin exposure and chronic hepatitis B are prevalent in many parts of the 
developing world, particularly in sub-Saharan Africa and Asia. It was estimated that 4.5 billion 
persons worldwide suffer from uncontrolled aflatoxins from dietary food 1. However, the global 
burden of HCC cases attributed to aflatoxin, individually and in conjunction with HBV 
infections, remained undefined. As previously reported by the Joint Food and Agriculture 
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Organization/World Health Organization Expert Committee on Food Additives (JECFA), the 
population attributable risk (PAR) fraction of aflatoxin as risk factor of liver cancer in Europe 
and the United States is “limited or none,” while in Africa and Asia, it is “not quantified” 13.  
An important input to decision-making and planning processes in health is a consistent 
and comparative description of the burden of diseases from the associated risk factors. Indeed, 
the Aflatoxin Workgroup 2 identified four issues that warrant immediate attention, including the 
following two: 1) quantifying human health impacts and burden of disease due to aflatoxin 
exposure, and 2) compiling an inventory, evaluating the efficacy, and disseminating results of 
ongoing intervention strategies.  
In this study we aimed to address these two crucial issues. We applied two different 
approaches to estimate the burden of aflatoxin-attributable liver cancer risk, at global level and in 
high exposure areas. In the first approach, we compiled available information on aflatoxin 
exposure and HBV prevalence from multiple nations in a quantitative cancer risk assessment, to 
estimate the number of HCC cases attributable to aflatoxin worldwide per year. In the second 
approach, we searched the literature, and selected cohort or case-control studies with reported 
odds ratios (ORs) or relative risks (RRs) of aflatoxin in relation to liver cancer, in areas with high 
aflatoxin exposures. By combining the relevant odds ratios (ORs) and relative risks (RRs) from 
these studies, we conducted meta-analyses to calculate population-attributable risk (PAR) of 
aflatoxin-related HCC in the population overall, as well as in HBV+ and HBV- populations. The 
model of combined effects between two risk factors – aflatoxin exposure and chronic HBV+, 
was also evaluated. 
This study is the first attempt to utilize the quantitative risk assessment and systematic 
approach to estimate the global burden of liver cancer attributable to aflatoxin exposure. This 
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study also examined the quantitative mode of combined effects between aflatoxin exposure and 
chronic hepatitis B from a meta-analysis. These numbers allow for a comparison of the relative 
importance of aflatoxin and chronic HBV infection as risk factors of liver cancer for various 
regions of the world. If the major contributor of aflatoxin-related hepatocellular carcinoma is the 
interaction with HBV infection, HBV vaccination may be sufficient to reduce the incidence of 
hepatocellular carcinoma associated with aflatoxin exposure 14. 
1.1 HUMAN TOXICOLOGY OF AFLATOXIN  
1.1.1 AFLATOXINS’ DISCOVERY AND METABOLISM IN HUMANS 
The first discovery of aflatoxins was due to the “turkey X” disease, an epidemic 
occurring in London in late 1950’s and early 1960’s, involving deaths of numerous turkey poults 
and ducklings which were fed with diets containing groundnuts imported from South America 15. 
Aflatoxins were discovered as the causative agents for this disease. Aflatoxins are a group of 
approximately 20 related fungal metabolites.  There are four major aflatoxins known as B1, B2, 
G1 and G2, plus two additional metabolic products, M1 and M2, found in milk and milk products 3. 
Aflatoxins B2 and G2 are the dihydro- derivatives of the parent compounds B1 and G1 16.  They 
were so named because of their strong blue or greenish-yellow fluorescence in ultraviolet light 
17. These properties facilitated the rapid development of methods in the early 1960s for 
monitoring grains and other food commodities for the presence of the toxins. The aflatoxins 
occur mostly in developing countries in tropical and sub-tropical areas between 40º N latitude 
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and 40º S latitude when the temperatures are between 24 and 35 °C and the moisture content 
exceeds 7% 1. They accumulate during the post-harvest storage under conditions that promote 
fugal growth.  
Humans are exposed to aflatoxins by consuming commodities contaminated during 
growth, harvest or storage. The levels of aflatoxin in the grain products may vary from less than 
1 µg/kg to greater than 12,000 µg/kg 18. In developed countries, harmful aflatoxin exposure has 
been mostly eliminated, thanks to the establishment of regulatory limits on traded foods, the 
enforcement of these limits through food monitoring, and the implementation of optimal drying 
and storage practices 2. However, it is difficult to apply these strategies in developing countries 
because of differences in food production, such as the prominence of subsistence farming in 
developing countries. Furthermore, these countries often lack the resources, technology, and 
infrastructure necessary for routine food monitoring as well as optimal drying and storage 
practices 19. And they often export the grain with best quality but keep the worst ones for their 
own consumption. In a recent outbreak of aflatoxicosis in Kenya, 55% of sampled maize 
products in local market had aflatoxin levels greater than the Kenyan regulatory limit of 20 ppb, 
35% had levels > 100 ppb, and 7% had levels > 1,000 ppb 19. Generally, diets may contain AFB1 
and AFB2 in concentration ratios of 1.0 to 0.1 and if all four aflatoxins occur, AFB1, AFB2, 
AFG1 and AFG2 are presenting at the proportion of 1.0:0.1:0.3:0.03 17. Among all the strains, 
aflatoxin B1 is the most abundant, toxic and most potent as a carcinogen 20. 
After dietary intake to human body, AFB1 is metabolized, mainly in the liver by 
cytochrome P450, to AFB1-8,9-exo-epoxide and AFB1-8,9-endo-epoxide. AFB1-8,9-exo-epoxide 
is much more toxic and active because it binds to DNA to form the predominant 8,9-dihydro-8-
(N7-guanyl)-9-hydroxy AFB1 (AFB1-N7-Gua) adduct 21, or binds to serum albumin to form long-
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lived lysine adducts 22. In addition, the epoxide can be conjugated by certain glutathione S-
transferases (GSTs) and then further metabolized to form aflatoxin-mercapturic acid 
detoxification product 23. The most prevalent mutation with AFB1-N7-Gua was demonstrated to 
be G to T transversions targeted to the site of the original adduct 24.  There are other metabolites 
formed from AFB1, including AFM1, AFQ1 and AFP1 25. These metabolites and other naturally 
occurring aflatoxins, AFG1, AFG2 and AFB2, are less mutagenic, carcinogenic and toxic than 
AFB1, because they are poorer substrates for epoxidation and the AFB1-8,9 exo-epoxide 
intercalates more readily into DNA 21,25.  Figure 1 illustrated the metabolism of aflatoxin B1 
leading to reactive metabolites and biomarkers (adapted from Wild and Turner 25) 
 
Figure 1. Principle metabolism of aflatoxin B1 leading to reactive metabolites and 
biomarkers 
(Figure is adapted from Wild C and Turner P, Mutagenesis 2002;17:471-48121) 
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1.1.2 AFLATOXIN AND HEPATOCELLULAR CARCINOMA 
Since their identification, 50 years of investigation on aflatoxins’ toxicity has revealed 
diverse adverse health effects related to dietary food contamination with aflatoxins, including 
acute aflatoxicosis, liver cancer, stunting in children, and immunosuppression effects. The link 
between aflatoxin exposure and both acute aflatoxicosis and liver cancer are well established 
4,6,26-30, whereas the association of exposure with stunting in children 31, immunosuppression 32,33 
remains tenuous but interesting and become increasing focus in studies.  
HCC is the third leading cause of cancer deaths worldwide with 749,000 cases and over 
695,000 deaths every year 34. 85% of the cases occur in developing countries. The regions of 
high incidence are Eastern and South-Eastern Asia, Middle and Western Africa where the 
incidence ranges from 10 to 100 cases per 100,000 per year 34. In developed countries, the rate of 
liver cancer incidence is much lower (1-10 cases/100,000/yr). Major risk factors for HCC 
include virus infection (HBV, HCV), alcoholism, smoking, environmental contaminants 
exposure such as arsenic and dietary aflatoxin, and the newly emerging risk factors in western 
developed countries, diabetes and obesity 35. Among all the risk factors, chronic HBV infection 
(determined by positive detection of hepatitis B surface antigen (HBsAg) twice 6 months apart), 
representing 300-400 million carriers worldwide, attribute to 54% of the global burden of liver 
cancer cases 36, and most of the cases occur in developing countries. Alcohol consumption and 
tobacco smoking are also clearly recognized as environmental risk factors of HCC, but the 
mechanisms of these factors, individually and in conjunction with viral infections are not well 
defined. In addition, HCC development varies depending on factors as the age, gender and host 
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genetic differences of the infected patients (reviewed in 37). It is also notable that chronic HBV 
or HCV infection rates show marked geographical differences which remain largely unexplained.   
Dietary aflatoxin is believed to play a major role in high HCC incidence in the 
developing world in Africa and Asia, because the occurrence of HCC and the high chronic HBV 
infection rates were observed coincident with the high, ubiquitous aflatoxin exposure in these 
areas. Early studies began in 1960s to investigate a possible ecological association between 
aflatoxin exposure and liver cancer 30. However, they were hindered by lack of the measurement 
of individual aflatoxin exposure and not taking into account HBV infection 12. Now, HCC as a 
result of chronic aflatoxin exposure has been well documented. The liver carcinogenicity of 
aflatoxin has been obtained from studies in many species of animals, including rodents, 
nonhuman primates and fish (reviewed in 17). In humans, the improvement of exposure 
assessment using biomarkers and the availability of prospective cohort studies in Asia revealed 
the significant interaction effects between aflatoxins and chronic HBV infection in inducing liver 
cancer 4,28,37,38. The risk of liver cancer in individuals exposed to chronic HBV infection and 
aflatoxin is up to 30 times greater than the risk in individuals exposed to aflatoxin only 18. 
Aflatoxin also appears to have a synergistic effect on HCV-induced liver cancer37,39,40, although 
the quantitative relationship is not as well-established as that for aflatoxin and HBV in inducing 
HCC.  
Chronic liver injury and regenerative hyperplasia resulting from HBV infection are 
critical to the development of liver cancer 41. However, the model of interaction between 
aflatoxins and HBV infection in liver cancer etiology has not been well understood yet. One 
possible mechanism is that aflatoxin-induced DNA adduct are fixed as mutations because of the 
HBV-related increase in cell proliferation and hyperplasia, thus promoting the mutant cells 
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expansion. Another possible mechanism is that HBV could predispose hepatocytes to the 
carcinogenic action of aflatoxins by altering the hepatic expression of aflatoxin metabolism 
enzymes and consequently the extent to which aflatoxins bind to DNA 42.  
Acute aflatoxicosis, characterized by jaundice, ascites, vomiting, abdominal pain, 
hepatitis and even death 43, has been described in humans exposed to 1-7 mg of aflatoxin daily 
for approximately 1-3 weeks 12. There have been sporadic historical reports of human 
aflatoxicosis in the developing world, including India, Kenya and Malaysia 26,44-46.  A more 
recent aflatoxicosis outbreak, occurred in Kenya 2004, resulted in 125 deaths and 317 cases 
41(mortality 39%) and the extent of contaminated maize consumption (geometric mean > 350 
ppb) was associated with the risk of aflatoxicosis 26.  
Aflatoxin and immunosuppression in humans has been relatively less well-characterized, 
but could in fact have enormous significance from a global health perspective 1.  Several recent 
human studies have shown evidence of immunomodulation 32,33,47 and this may be one 
explanation for the stunted growth in children that appears to follow a dose-response relationship 
with aflatoxin exposure 31,33,48, though the actual outcomes of such immunomodulation have yet 
to be characterized in humans.  Another explanation may be altered intestinal integrity 49. 
In this study we focus on the liver carcinogenicity of aflatoxins, because this is the most 
extensively studied feature of aflatoxin toxicology in humans with well-established data to 
conduct the risk assessment. 
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1.1.3 AFLATOXIN BIOMARKERS 
Biomarkers of exposure, internal dose and the biologically effective dose of aflatoxins 
are most commonly used for assessing exposure or intervention in epidemiological studies. A 
biomarker of exposure refers to measurement of the specific interactive products in human body 
compartment or fluid and indicates the presence and magnitude of current and past exposures. 
Biomarkers of an internal dose and a biological effective dose for aflatoxins reflect the presence 
and magnitude of a biological response to aflatoxin exposure 17. The knowledge of aflatoxin 
metabolism and carcinogenesis in humans provides the basis for the development of aflatoxin 
biomarkers, and the use of biomarkers to measure exposure and determine risk. 
Urinary measures of AFM1, AFB1-mercapturic acid and serum aflatoxin-albumin adducts 
are used as biomarkers of internal dose 21,50,51, while AFB1-N7-guanine in urine serves as a 
biomarker of biologically effective dose 17. The measurement of aflatoxin-DNA and protein 
adducts are of major interest because they are derived from the carcinogenic species aflatoxin-
8,9-exo-epoxide 52. Measurements of aflatoxin biomarkers in urine reflect recent exposure, while 
aflatoxin-albumin adducts in serum reflect cumulative exposures over the past 2-3 months 53. 
Indeed, studies conducted in China and The Gambia, both areas with high incidences of HCC, 
determined that the levels of urinary aflatoxin biomarkers (aflatoxin M1 and aflatoxin-N7-
guanine) followed a dose-response relationship with dietary aflatoxin intake 50,54. Similarly, 
significant association between dietary aflatoxin intake and aflatoxin-albumin levels was 
observed 51,55. More recently, a positive correlation has been shown between population 
estimates of aflatoxin exposure and the proportion of HCC patients with TP53 249ser mutation 5. 
The TP53 249ser mutation occurrence is common in HCC patients in geographic regions with 
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high aflatoxin exposure, such as Qidong, China and The Gambia, Africa 41. However, this 
mutation is rare in areas with low aflatoxin exposure such as Europe and the United States. This 
finding suggested that the detection of TP53 249ser mutation may be used as a biomarker of an 
early neoplastic event, chronic exposure to aflatoxin or a combination of both. Indeed, this 
finding has led to the application of this marker in population-based studies 5,56-58.  
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2.0  GLOBAL BURDEN OF AFLATOXIN-INDUCED HEPATOCELLULAR 
CARCINOMA: A RISK ASSESSMENT 
The Joint Expert Committee on Food Additives (JECFA) of the Food and Agriculture 
Organization (FAO) and World Health Organization (WHO) undertook an aflatoxin-HCC risk 
assessment in 1998, to estimate the impact on population liver cancer incidence by moving from 
a hypothetical total aflatoxin standard of 20 ng/g to 10 ng/g 20,59.  Assuming that all food that 
contained higher aflatoxin levels than the standard was discarded, and that enough maize and 
nuts would remain to preserve consumption patterns, JECFA determined that HCC incidence 
would decrease by about 300 cases per billion people per year, if the stricter aflatoxin standard 
were followed in nations with HBV prevalence of 25%.  However, in nations where HBV 
prevalence was 1%, the stricter aflatoxin standard would only save 2 HCC cases per billion 
people per year.  This assessment associated HCC risk with particular doses of aflatoxin; 
however, these doses do not correspond with actual doses in food in different parts of the world, 
and the two hypothetical values for HBV prevalence, 1% and 25%, were not intended as a 
complete global assessment.  
 Shephard 2008 48 estimated population risk for aflatoxin-induced HCC in select African 
nations; we expand this to include the rest of the world.  We also briefly describe interventions 
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that have been developed to either reduce aflatoxin directly in food, or to reduce adverse health 
effects caused by aflatoxin. 
2.1 METHODS 
We analyzed extensive datasets by nation or world region: food consumption patterns 
(specifically of maize and peanuts), aflatoxin levels in maize and peanuts, HBV prevalence, and 
population size, in order to perform a quantitative cancer risk assessment for aflatoxin-related 
liver cancer.  Risk assessment is the process of estimating the magnitude and the probability of a 
harmful effect to individuals or populations from certain agents or activities. Four steps are 
involved in estimation of the risk: hazard identification, dose-response analysis, exposure 
assessment, and risk characterization 60.    
2.1.1 HAZARD IDENTIFICATION  
Hazard identification is the process of determining whether exposure to an agent can 
increase the incidence of a particular health condition.  Aflatoxin exposure is associated with an 
increase in incidence of HCC in humans and sensitive animal species 18; indeed, IARC has 
classified aflatoxin B1 (AFB1) as a Group 1 carcinogen 3.   
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2.1.2 DOSE-RESPONSE ANALYSIS   
This second risk assessment step involves characterizing the relationship between the 
dose of an agent – in this case, aflatoxin - and incidence of HCC.  Because of the synergistic 
impact of aflatoxin and HBV in inducing HCC, the assessment must be done separately for 
populations with and without chronic HBV infection.  Though chronic HCV infection may also 
have synergistic effects with aflatoxin in inducing HCC, this was not included because: 1) there 
is much less overlap worldwide between aflatoxin and HCV exposures in general; 2) chronic 
HCV infection usually occurs later in life while chronic HBV infection occurs much earlier; 
hence, the time of overlapped exposure is less significant for aflatoxin and HCV (Dr. John 
Groopman, personal communication); and 3) much less is known about the quantitative 
relationship of aflatoxin and HCV in inducing HCC. 
For cancer risk assessment, it is traditionally assumed that there is no threshold of 
exposure to a carcinogen below which there is no observable adverse effect 61.  Cancer potency 
factors are estimated from the slope of the dose-response relationship, assumed to be linear, 
between doses of the carcinogenic agent and cancer incidence in a population.  The JECFA 
aflatoxin risk assessment had selected two different cancer potency factors for aflatoxin: 0.01 
cases per 100,000 per year per ng/kg bw/day aflatoxin exposure for individuals without chronic 
HBV infection, and 0.30 corresponding cases for individuals with chronic HBV infection.  This 
was based on one cohort study that estimated cancer potency in both HBsAg+ (HBV surface 
antigen: a biomarker of chronic HBV infection) and HBsAg- individuals 30 as well as other 
human studies that assessed cancer potency in either HBsAg+ or HBsAg- individuals. We used 
these same potency factors for this risk assessment.  Because only one of the studies 30 
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specifically assessed cancer potency in both cohorts, there may be considerable uncertainty 
associated with these potency factors.  However, several epidemiological studies confirm that 
aflatoxin’s cancer potency is about 30 times greater in HBV+ compared with HBV- individuals 
5,6,62.  
2.1.3 EXPOSURE ASSESSMENT 
 Exposure assessment involves estimating the intensity, frequency, and duration of 
human exposures to a toxic agent.  Specifically, we sought to determine how individuals’ 
exposure to aflatoxin increases their risk of HCC, which is depending on whether they are 
chronically infected with HBV.  Aflatoxin exposure is a function not only of aflatoxin 
concentrations in maize and nuts, but also of how much of these foodstuffs individuals consume 
in different parts of the world. 
Aflatoxin exposure assessment has evolved significantly over the last two decades, 
largely due to the characterization of biomarkers for both aflatoxin exposure and effect 63.  Prior 
to these biomarkers, the primary way by which aflatoxin exposure was estimated was to observe 
how much maize and nuts people consumed on average by world region; and to measure or 
assume aflatoxin levels in these foods.  However, by measuring biomarkers such as aflatoxin-
albumin adducts in serum or aflatoxin-N7-guanine in urine, it is possible to improve estimations 
of aflatoxin exposure and of how much has been biotransformed to increase cancer risk 18.   
As data do not exist on aflatoxin biomarker levels in most parts of the world, we 
estimated average aflatoxin exposure or contamination levels in the maize and nuts in different 
world regions by collecting data on estimated HBV prevalence in these countries, maize and nut 
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consumption patterns in different world regions, and. Where aflatoxin exposure data were not 
already estimated, we used food consumption patterns and aflatoxin contamination levels to 
estimate exposure.  The studies estimating HBV prevalence were based on HBsAg detection in 
males and females in both urban and rural settings across all age groups.  Data on maize and 
peanut consumption in different parts of the world are adapted from the WHO Global 
Environment Monitoring System (GEMS) Food Cluster Diet database 64.  Aflatoxin exposure 
data in different nations were estimated from multiple different sources through literature 
searches.   
2.1.4 RISK CHARACTERIZATION  
This final step of risk assessment integrates dose-response and exposure data to describe 
the overall nature and magnitude of risk.  For our study, this final step consisted of quantifying, 
across the globe, the burden of aflatoxin-related liver cancer.  For each nation, we estimated total 
number of individuals with or without chronic HBV by multiplying prevalence by population 
size.  To estimate aflatoxin-induced HCC cases per 100,000 in these two populations (with and 
without chronic HBV infection), we multiplied the corresponding cancer potency factor by 
aflatoxin exposure estimates.  Then we multiplied these values by the nations’ HBV+/HBV- 
population sizes, divided by 100,000, to derive total number of aflatoxin-induced HCC cases in 
each nation.  We summed across all world regions to arrive at an estimate for global burden of 
aflatoxin-induced HCC. 
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The risk characterization model: 
Population liver cancer risk caused by aflatoxin = Potency of aflatoxin * Average 
aflatoxin daily intake*population 
In which, Potency = [Potency factor of AF for HBV+ persons] * [% of HBV+ persons]  
 + [Potency factor of AF for HBV- persons] * [% of HBV- persons]  
2.2  RESULTS 
2.2.1 THE PREVALENCE OF CHRONIC HBV INFECTION BY WORLD REGION 
Table 1 lists the age-adjusted prevalence of chronic HBV infection by world region, as 
measured by the seroprevalence of HBsAg in different parts of the world.  Though there is 
uncertainty and variability in these different estimates, all data are from literature published on or 
after 2000, to ensure HBV prevalence estimates that are as updated and relevant as possible.  
Countries are grouped by WHO designated regions 65: Africa, Eastern Mediterranean, Europe, 
America, Southeast Asia, and Western Pacific Region.  Some regions are further divided into 
subgroups, because of significantly varied aflatoxin exposure and HBV prevalence within the 
region.  
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 Table 1. Estimates of HBV prevalence based on HBsAg Seroprevalence in select countries  
WHO Region Countries  Chronic HBV Prevalence (HBsAg Seroprevalence, range) 
Africa Dem. Repub. Congo 6-10% 66,67 
Ethiopia 6-7% 68,69 
The Gambia 15-20% 70,71 
Kenya 11-15% 72,73 
Mozambique 4.5-10.6% 74 
Nigeria 13.2% 75 
South Africa 3.3-10.4% 72,76 
Tanzania 5-9% 77-79 
Zimbabwe 10-15% 72,80 
Others 9-20% 72,79,81 
 
 North America  
  
 
Canada 1-2% 82,83 
United States  0.3- 2% 65,84,85 
Latin America Argentina 0.8-1.1% 86,87 
Brazil 2.1-3.4% 86,87 
Mexico <0.3% 88 
Others  0.5-3% 86,87 
 
Eastern Mediterranean Egypt 2.2-10.1% 89-91 
Iran 0.41-0.56% 92,93 
Pakistan 3.3% 94,95 
Sudan 6-26% 96 
Others 0.65-10% 65,97-99 
South-East Asia India  2.4- 4.7% 76,100,101 
Indonesia 2.5-5% 102-104 
Thailand  4.6-8% 76,105 
Others 2-7% 65,106-108 
 
Western Pacific Region Australia <1% 109 
China  8-10% 102,109 
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Malaysia 5% 102,109 
Philippines 5-16% 109-111 
Korea  4-5% 109,112 
Others 1-10% 102,113,114 
 
Europe Eastern Europe 2-7% 115,116 
Southern Europe 2-7% 65,117,118 
Western Europe  0.5-1% 65,119,120 
 
Table 1 continued 
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2.2.2 THE MAIZE AND PEANUT CONSUMPTION PATTERN IN SELECTED 
COUNTRIES OF THE WORLD 
Table 2 contains calculations of maize and peanut consumption in select countries of the 
world.  The GEMS/Food Consumption Cluster Diets database divides countries of the world into 
thirteen groups based upon diets 64.  For each group cluster, the GEMS/Food Consumption 
database has estimated the amount of cereals, nuts and oilseeds consumed. We thus estimated 
average maize and nut consumption by individual country.  There are limitations to these data 
because of the clustering into thirteen groups (which may lead to wide ranges among nations 
within a group), as well as variability in data quality regarding diet and aflatoxin exposure 
estimates. 
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Table 2. Maize and peanut consumption in select countries, adapted from GEMS/Food Cluster Diet database 
WHO Region      Countries or Populations Maizei 
(g/person/day) 
        Peanutii 
(g/person/day) 
Africa Dem. Rep. Congo 57 52 
Ethiopia 83 13 
Gambia 57 52 
Kenya 248 11 
Mozambique 248 11 
Nigeria 57 52 
South Africa 248 11 
Tanzania 248 11 
Zimbabwe 248 11 
North America 
 
 
 
Canada 86 17 
United States  86 17 
Central and South America Argentina 86 17 
Brazil 63 2 
Mexico 300 5 
Eastern Mediterranean Egypt 136 5 
Iran 32 2 
Pakistan 35 18 
Sudan 57 52 
 
Southeast Asia India  35 18 
Indonesia 35 18 
Thailand  35 18 
                                                 
i Including maize, flour and germ.   
 
ii Including groundnuts in shell and shelled 
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Western Pacific Region Australia  86 17 
China  35 18 
Malaysia 35 18 
Philippine 59 2 
Republic of Korea 59 2 
 
Europe Eastern Europe 32 2-10 
Southern Europe 148 7 
Western Europe  33 10 
Table 2 continued 
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2.2.3 ESTIMATED AFLATOXIN EXPOSURE AND HCC INCIDENCE 
ATTRIBUTABLE TO AFLATOXIN BY WHO REGION  
We estimated (based on the data in Tables 1 and 2) or found in the literature the average 
aflatoxin exposure in different world regions.  These are listed in the middle column of Table 3.  
The rightmost columns of Table 3 contain calculations for the estimated incidence of aflatoxin-
induced HCC, with and without the synergistic impact with HBV, in the corresponding 
populations of each nation and world region. Specifically, within each WHO-designated region, 
aflatoxin exposures in the most populous nations were found.  The “in general” rows in Table 3 
represent a small proportion of each region: nations in which aflatoxin data were not available, or 
very small nations.  For these, we assumed a range for aflatoxin exposure that incorporated the 
ranges of the nations within the region for which aflatoxin data were found.   
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Table 3. Estimated HCC incidence attributable to aflatoxin by WHO region 
WHO Region Countries or 
Populations 
 
Aflatoxin exposure 
(ng/kg body weight/daya) 
Estimated HCC incidence 
attributable to aflatoxin, 
HBsAg- (/100, 000/yr) 
Estimated HCC incidence 
attributable to aflatoxin 
exposure, HBsAg+ (/100, 000/yr)  
Africa Dem. Rep. Congo 0.07-27 b 121 0.0007-0.27 0.02-8.10 
Ethiopia 1.4-36 b 122  0.01-0.36 0.42-10.8 
The Gambia 4-115 48,123  0.04 – 1.15 1.20 – 34.5 
Kenya 3.5 – 133 48,123 0.04 – 1.33 1.05 – 39.9 
Mozambique 39-180 123 0.39-1.80 11.7 – 54.0 
Nigeria 139-227 b 124,125 1.39-2.27 41.7-68.1 
South Africa 0-17 123,126 0-0.17 0-5.10 
Tanzania 0.02-50 b 121  0.0002-0.50 0.06-15.0 
Zimbabwe 17.5-42.5 20 0.18-0.43 5.25-12.8 
In general c 10-180 48,123 
 
0.10-1.80 3.0-54.0 
North America  
 
 
 
 
Canada 0.2-0.4d 127 0.002 – 0.004 0.06-0.12 
United States  0.26 20 0.003 0.08 
In general c 0.26-1 0.003-0.01 0.08-0.3 
 
Latin America Argentina 0-4 b 128,129  0-0.04 0-1.20 
Brazil 0.23-50 b 3,130-132  0.002-0.50 0.07-15.0 
Mexico 14-85 b 133-135 0.14-0.85 4.20-25.5 
 In general c 20-50 0.20-0.50 6.0-15.0 
 
Eastern 
mediterranean 
Egypt 7-57 b 136 0.07-0.57 2.1-17.1 
Iran 5-8.5 b 137,138 0.05-0.09 1.50-2.55 
Pakistan 7-50 b 139  0.07-0.50 2.10-15.0 
Sudan 19-186 28 0.19-1.86 5.70-55.8 
In general c 10-80 0.10-0.80 3.00-24.0 
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South-East 
Asia 
India  4-100 140 0.04-1.00 1.20-30.0 
Indonesia 9-122 b 3,141,142 0.09-1.22 2.7-36.6 
Thailand  53-73 123,143b 0.53-0.73 15.9-21.9 
In general c 30-100 0.30-1.00 9.00-30.0 
 
Western 
Pacific Region  
Australia iii 0.15 -0.18 16,144 ~0.002 ~0.05 
China  17-37 b 6,145-147 0.17-0.37 5.10-11.1 
Malaysia 15-140 b 3,148 0.15-1.4 4.5-42 
Philippine 44-54 b 3,148,149  0.44-0.54 13.2-16.2 
Republic of 
Korea 
1.2-6 62,150 0.01-0.06 0.36-1.80 
In general c 15-50 (except Australia & 
New Zealand) 
 
0.15-0.50 4.5-15.0 
Europe Eastern Europe 3.5-4 e 151  0.04 ~1.20 
Southern Europe 0-4 f 152,153 0-0.04 0-1.20 
Western Europe  0.3-1.3 154 0.003-0.01 0.09-0.39 
 In general c 0-4 0-0.04 0-1.2 
 
a Assuming 60 kg bodyweight per individual 
b Aflatoxin exposure was estimated by multiplying aflatoxin concentrations in staple foods by consumption rates of those foods 64. 
c  “In general” line summarized the aflatoxin exposure estimates, the estimated HCC incidence attributable to aflatoxin in HBV+ and HBV- 
individuals for all other countries classified in the same WHO region. 
d 1-2 ng/kg bw/day was measured in children’s diets; here we assume the adult daily aflatoxin intake is 20% of children’s.  
e Average daily aflatoxin intake was estimated based on AFB1contamination levels in Czech maize, multiplied by average daily maize 
consumption in Eastern Europe.   
f Average daily aflatoxin intake was estimated based on AFB1contamination levels in maize of North Italy and Turkey, multiplied by average 
daily maize consumption in Southern Europe. 
                                                 
 
Table 3 continued 
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2.2.4 ESTIMATED GLOBAL BURDEN OF HCC CASES ATTRIBUTABLE TO 
AFLATOXIN EXPOSURE IN HBSAG+ AND HBSAG- POPULATION 
These data provide the necessary information to calculate the total estimated cases 
of aflatoxin-induced HCC cases annually, worldwide.  Populations for each relevant 
nation and world region are listed in Table 4.  Accounting for chronic HBV infection 
prevalence as shown in Table 1, and the risk incidence estimates for HBV+ vs. HBV- 
individuals in Table 3, the numbers of cases of aflatoxin-induced HCC can be estimated 
in each world region.  These are then summed to produce a global estimate of the number 
of annual aflatoxin-induced HCC cases.  Our estimate is that anywhere from 25,200-
155,000 annual HCC cases worldwide may be attributable to aflatoxin exposure. 
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Table 4. Estimated global burden of HCC cases attributable to aflatoxin exposure in HBsAg+ and HbsAg- population 
 
WHO Region Countries or 
Populations 
Population  
155 
HCC cases attributed 
to aflatoxin, HBsAg- 
HCC cases attributed to 
aflatoxin, HBsAg+ 
Africa Dem. Rep. 
Congo 
68 million 1-173 1-551 
Ethiopia 85 million 11-288 21-643 
Gambia 1.7 million 1-17 3-117 
Kenya 38 million 11-450 44-2,270 
Mozambique 21 million 73-361 111-1,200 
Nigeria 149 million 1,800-2,940 8,200-13,400 
South Africa 48 million 0-79 0-255 
Tanzania 41 million 1-195 1-554 
Zimbabwe 13 million 19-50 68-249 
Total Region 755 million 2,150-9,300 9,230-50,600 
North America 
 
 
 
Canada 33 million 1 1 
United States  300 million 8 1-5 
Total Region 333 million 9 2-5 
Central and South America Argentina 40 million 0-16 0-5 
Brazil 190 million 4-930 3-969 
Mexico 109 million 152-924 14-83 
Total Region 562 million 589-2,980 84-2,060 
Eastern Mediterranean Egypt 81 million 51-452 37-1400 
Iran 66 million 33-56 4-9 
Pakistan 172 million 116-832 119-851 
Sudan 41 million 58-717 140-5,950 
Total Region 569 million 446-3,720 341-13,200 
South-east Asia India  1.15 billion 438-11,200 331-16,200 
Indonesia 237 million 203-2,820 160-4,340 
Thailand  63 million 307-439 461-1,100 
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Total Region ~1734 million 1,740-17,300 1,460-27,600 
 
 
Western Pacific Region Australia  21 million 0-1 0-1 
China  1.3 billion 1,990-4,430 5,300-14,400 
Korea 50 million 5-29 6-45 
Malaysia 28 million 40-372 63-588 
Philippine 90 million 333-462 594-2,330 
Total Region ~ 1740 million 2,710-6,510 6,310-21,200 
 
 
Europe  Eastern Europe 290 million 94-114 61-244 
Southern 
Europe 
144 million 0-56 0-121 
Western 
Europe 
183 million 5-24 1-7 
Total Region 617 million 99-184 62-372 
 
Total (World) 6.28 billion 7,700-40,000 17,500-115,000 
Total annual HCC cases attributable to aflatoxin 
worldwide 
25,200-155,000 
Table 4 continued 
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Figure 2 illustrates the distribution of total HCC cases attributable to aflatoxin globally. 
The categories denote WHO world regions.  Sub-Saharan Africa is the most important region as 
far as HCC cases attributable to aflatoxin; Southeast Asia and China (in the Western Pacific 
region) are also key regions where aflatoxin exposure is an important risk factor for HCC.  
Relatively fewer cases occur in the Americas, the Eastern Mediterranean, and Europe.  Though 
Australia and New Zealand are grouped with the Western Pacific Region, these nations also have 
low aflatoxin-induced HCC incidences. 
 
Figure 2. Distribution of HCC cases attributable to aflatoxin in different regions of 
the world 
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2.2.5 THE REDUCED GLOBAL BURDEN OF AFLATOXIN-INDUCED LIVER CANCER 
UNDER A HYPOTHETICAL SCENARIO OF SUCCESSFUL HBV VACCINATION PROGRAM 
WORLDWIDE 
Vaccination is the most effective public health intervention to reduce the global incidence 
of hepatitis B. In 1991, the WHO recommended that all countries introduce a policy of universal 
hepatitis B vaccination by 1997 to prevent and control on a global scale HBV infection and 
ultimately, the incidence of HCC 156.  In countries with high (HBsAg > 8%) or intermediate 
disease endemicity (HBsAg 2%-8%), the most effective strategy is to incorporate the vaccine 
into the routine immunization schedule for newborn infants (<24h). Since 1997, substantial 
progress has been made in implementing this recommendation. In 2008, 177 WHO member 
states have introduced hepatitis B vaccine in routine infant immunization and 82 countries 
provided vaccine for infant at birth 157. Because the aflatoxin cancer potency increases 30 times 
when the exposure is in conjunction with chronic hepatitis B, the decreasing chronic hepatitis B 
incidence will also substantially reduce the aflatoxin-attributable HCC incidence in the long 
term. As the effectiveness of massive vaccination will be seen in the next 20-30 years, we 
assumed a hypothetical scenario that universal infant HBV vaccination program was provided 
globally and successfully reduced chronic HBV infection prevalence to lower than 2% 
worldwide. We then estimated the global burden of HCC cases that aflatoxin will be attributable, 
individually and in conjunction with chronic HBV infection. We assume the food consumption 
pattern, the aflatoxin daily intake and the population remain the same as that we applied in the 
previous calculation for estimating the global burden of aflatoxin-induced liver cancer. 
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Our estimates were presented in Table 5. With ≤ 2% HBsAg seroprevalence worldwide, 
the annual number of aflatoxin-related HCC cases will be 13,420-65,400, a reduction of 50%. 
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Table 5. The estimated reduced global burden of HCC cases attributed to aflatoxin  
WHO Region Countries or Populations Population  
 
Estimated HCC cases 
attributed to 
aflatoxin, HBsAg- 
Estimated HCC cases 
attributed to aflatoxin, 
HBsAg+ 
Africa  Democratic Republic of Congo 68 million 0-180 0-110 
Ethiopia 85 million 12-300 7-184 
Gambia 1.7 million 1-19 0-12 
Kenya 38 million 13-495 8-303 
Mozambique 21 million 80-370 49-227 
Nigeria 149 million 2,030-3,315 1,243-2,029 
South Africa 48 million 0-80 0-49 
Tanzania 41 million 0-201 0-123 
Zimbabwe 13 million 22-54 14-33 
Total Region 755 million 2,442-10,135 1,495-6,205 
North America  Canada 33 million 1 0 
United States  300 million 8 1 
Total Region 333 million 9 1 
Central and South Argentina 40 million 0-16 0-4 
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America Brazil 190 million 4-931 3-570 
Mexico 109 million 152-924 14-83 
Total Region 562 million 600-2,980 84-824 
Eastern 
Mediterranean 
Egypt 81 million 56-452 34-277 
Iran 66 million 33-56 4-7 
Pakistan 172 million 118-843 72-516 
Sudan 41 million 76-747 47-458 
Total Region 569 million 488-3,737 282-2,261 
South-east Asia India  1.15 billion 451-11,270 276-6,900 
Indonesia 237 million 209-2,834 128-1,735 
Thailand  63 million 327-451 200-276 
Total Region ~1734 million 1,822-17,338 1,115-10,615 
Western Pacific 
Region 
Australia  21 million 0 0 
China  1.3 billion 2,166-4,714 1,326-2,886 
Korea 50 million 5-29 3-18 
Malaysia 28 million 41-384 25-235 
Philippine 90 million 388-476 238-292 
Total Region ~ 1740 million 2,969-6,833 1,818-4,184 
Europe  Eastern Europe 290 million 99-114 61-70 
Table 5 continued 
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Southern Europe 144 million 0-56 0-35 
Western Europe 183 million 5-24 1-4 
Total Region 617 million 104-194 62-109 
Total (World) 6.28 billion 8,514-41,226 4,906-24,199 
Total annual aflatoxin-induced HCC cases 13,420-65,400 
 
Note: when a worldwide universal HBV vaccination program is accomplished, we assume 2% HBsAg prevalence in areas of moderate to 
high HBV prevalence
Table 5  continued 
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2.3 DISCUSSION 
Aflatoxin contamination of food is a serious global health problem, particularly in less 
developed countries.  Though it has been known for several decades that aflatoxin causes liver 
cancer in humans, the exact burden of aflatoxin-related HCC worldwide has been unknown.  
This study represents a first step in attempting to estimate that burden.  We find that at its lower 
estimate, aflatoxin plays a role in about 4.6% of total annual HCC cases; while at its upper 
estimate, aflatoxin may play a role roughly 28.2% of all HCC cases worldwide.  This large range 
stems from the considerable uncertainty and variability in data on cancer potency factors, HBV 
prevalence, and aflatoxin exposure in different world regions.  The most heavily afflicted parts of 
the world are sub-Saharan Africa, Southeast Asia, and China.  It is notable that Mexico may bear 
high aflatoxin exposure from contaminated food, and the resulted 152-924 HCC cases per 
100,000 per year indicated aflatoxin could be a significant factor of HCC incidences in this 
country, despite the fact that the chronic HBV prevalence is relatively low in this country (< 
0.3%).  
Aflatoxin exposure varied within and between populations. Developing countries in 
tropical and sub-tropical areas are nearly ubiquitously exposed to moderate-to-high levels of 
aflatoxin from contaminated food.  Aflatoxin is a controllable risk factor in food; yet the parts of 
the world in which the risk is particularly high have limited resources to implement most 
aflatoxin control strategies.  Much agricultural land in Africa and Asia lies in climatic regions 
favorable for A. flavus and A. parasiticus proliferation. Suboptimal field practices and poor 
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storage conditions make the crops vulnerable to fungal infection and subsequent aflatoxin 
accumulation. Maize and groundnuts, the two crops most conducive to Aspergillus infection, are 
staples in many African and Asian diets.  Because the very poor in these regions cannot afford 
much variety in their food, these particular staples make up a significant portion of their diets, 
increasing aflatoxin exposure.  
Even within the same population, aflatoxin exposure varied geographically. Studies have 
shown that rural populations generally have higher levels of AFB1 adducts than urban dwellers in 
developing countries 158 because urban people consume more diversified diets than rural 
dwellers. In addition, there is a strong seasonal variation in AFB1 exposure which correlates with 
the food availability 159,160.  
Patterns and acquisition of chronic HBV infection vary geographically. Horizontal 
transmission is predominant in West Africa where HBsAg prevalence in infants and young 
children can be between 15%-20% 161. Parenteral, drug use and sexual contact are the common 
modes of HBV transmission in most Western countries. In contrast, perinatal transmission is the 
most important reason for chronic HBV acquisition in Southeast Asia and Western-Pacific 
countries.  The chronic HBV prevalence is generally higher in rural than in urban areas, and 
higher in males than females in most places. Our collected data of HBsAg seroprevalence are 
presented as a range for countries/populations, to take into consideration these variations.  
This analysis focuses on carcionogenic aflaoxin, individually and in conjunction with 
chronic HBV carriage, to define the global burden of HCC attributed to aflatoxin. However, the 
role of aflatoxin in conjunction with other carcinogens, such as alcohol consumption, and host 
genetic differences in contributing to HCC development, is still undefined. 
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Though many nations that suffer from both high aflatoxin exposures and high HBV 
prevalence have nominally established maximum allowable aflatoxin standards in food, there is 
little if any enforcement of these standards in many rural areas.  Indeed, the food in subsistence 
farming and local food markets is rarely formally inspected. When trading with other nations, 
strict aflatoxin standards can even lead to large economic losses for poor food-exporting nations 
162. Subsistence farmers and local food traders sometimes have the luxury of discarding 
obviously moldy maize and groundnuts. But in drought seasons, oftentimes people have no 
choice but to eat moldy food or starve 163. 
Multiple public health interventions exist by which to control aflatoxin or its burden in 
the body, to prevent HCC. These interventions are grouped into three categories: 1) Agricultural, 
2) Dietary, and 3) Clinical. Agricultural interventions are methods or technologies that can be 
applied either in the field (“preharvest”) or in storage and transportation (“postharvest”) to 
reduce aflatoxin levels in food. Agricultural interventions can thus be considered “primary” 
interventions, because they effectively reduce aflatoxin in food before it reaches the consumer’s 
plate. Dietary and clinical interventions can be considered “secondary” interventions. They 
cannot reduce actual aflatoxin levels in food, but they can reduce aflatoxin-related illness; either 
by reducing aflatoxin’s bioavailability in the body or by ameliorating aflatoxin-induced damage. 
Because aflatoxin-mediated mutations may precede HCC by several years, the effects of 
reducing aflatoxin exposure on HCC incidence may take time to become apparent 164. 
One highly effective clinical intervention to reduce aflatoxin-related HCC is vaccination 
against HBV. A regular practice now in the U.S. and other industrial nations, HBV vaccination 
in children is now becoming more common worldwide. Vaccinating children against HBV has, 
over the last 30 years, significantly decreased HBV infection in several regions including Europe 
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165,166, Taiwan 167 and Thailand 168. For example, in Taiwan, the nationwide infant vaccination 
program for hepatitis B launched in 1984 significantly reduced the prevalence of HBsAg from 
14.3% in 1995 to 1.1% in 2009 167. This vaccine has been and will continuously have significant 
impacts on liver cancer incidence worldwide over time. In our hypothetical scenario of HBV 
vaccination being made instantaneously available worldwide, the estimated number of HCC 
cases attributable to aflatoxin in the next generation, absent other changes, would drop 42-53%.; 
because removing a possible synergistic impact between HBV and aflatoxin exposure would 
significantly reduce HCC risk. However, there are currently 360 million chronic HBV carriers 
worldwide and HBV vaccine is still not incorporated into many national immunization programs 
169. Thus measures to reduce food spoilage by fungi and the associated dietary exposure to 
aflatoxins are also a desirable public health goal. 
Our study highlights the significant role of aflatoxin in contributing to global liver cancer 
burden.  While it is impossible to completely eliminate aflatoxin in food worldwide, it is possible 
to significantly reduce levels and dramatically reduce liver cancer incidence worldwide.  The 
interventions described are first steps in reducing aflatoxin-induced liver cancer, but the 
challenge remains to deliver these interventions to places of the world where they are most 
needed. 
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3.0  VALIDATION OF THE AFLATOXIN-INDUCED LIVER CANCER RISK 
ASSESSMENT MODEL – A CASE STUDY IN FUSUI, GUANGXI, CHINA  
Previously, we developed a risk assessment model to estimate the liver cancer risk caused 
by aflatoxin dietary intake alone and in combination with chronic HBV infection status at global 
level. Variables in the model include chronic HBV infection prevalence, aflatoxin contamination 
levels in food and the food consumption data in multiple nations. To validate this model, we 
picked a specific area of China to examine how this model will perform when it is applied to a 
particular area instead of global scale. The process of model validation also allows us to to 
conduct the sensitivity analysis, to analyze how the inputs to each variable will influence the 
results.  Sensitivity analysis is a systematic technique used to understand how risk-based 
decisions are dependent on variability and uncertainty in the factors contributing to risk. In this 
chapter, we assigned different values to the key variables in the model based upon the data from 
epidemiological studies conducted in this area. Then we compared the estimated disease burden 
from the model, to the actual epidemiology surveillance data in the area. We also compared the 
results to determine the importance of the variables in the model.  
China was selected to be the particular country to conduct the validation analysis 
because: 1) China is among the countries with both high prevalence of aflatoxin exposure and 
chronic HBV infection rates; 2) epidemiological evidences indicated that the HBV prevalence 
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and aflatoxin exposure in China are decreasing in the past 30 years due to the nationwide infant 
vaccination program, as well as the noticeable change in diet style in the areas with high 
aflatoxin exposure 164; 3) extensive human study data are available on the association between 
aflatoxin and liver cancer risk in China, so that we have relatively more data sources to conduct a 
sensitivity analysis compared to other affected countries/areas. In addition, we specifically 
picked the Fusui County to do analysis because other than the above reasons, the chronic HBV 
infection and dietary aflatoxin exposure are the two major risk factors for HCC in Fusui, China, 
while the hepatitis C virus infection is extremely uncommon  this area.  
The objectives of this case study are: 1) to assess the reliability of the conclusions and 
inferences drawn from the previous risk assessment model; 2) to identify the key variables that 
influence the liver cancer risk in the proposed risk assessment model; and 3) to assess the benefit 
of different interventions to reduce the liver cancer risk in the affected population. 
3.1 METHODS 
We collected food consumption data which reflect the changing of diet style in local 
population, the aflatoxin contamination level in consumed food, and the chronic HBV infection 
rates in Fusui, China, from 1970s to 2010s. We then calculated and compared the results derived 
from applying the changed values to the variables in the model.  
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3.1.1 IDENTIFICATION OF THE KEY VARIABLES IN THE RISK ASSESSMENT 
MODEL 
In Chapter 2, we applied the below model to characterize the liver cancer risk attributable 
to aflatoxin: 
Population liver cancer risk caused by aflatoxin = Potency of aflatoxin * Average 
aflatoxin B1 daily intake*population 
In which, Potency = [Potency factor of AF for HBV+ persons] * [% of HBV+ persons]  
 + [Potency factor of AF for HBV- persons] * [% of HBV- persons]  
We analyzed the quantifiable determinants and the underlying determinants for each 
variable in the model, presented in Table 6. To quantitatively validate the model, the average 
dietary aflatoxin B1 intakes for the population of Fusui in different years were estimated based on 
the daily food intakes and concentration of AFB1 detected in food samples. The age-adjusted 
HBV prevalences were also estimated and the percentage of HBV- persons was estimated as (1- 
[% of HBV+ persons]). We first adopted the potency factors of aflatoxin in HBV+ persons and 
HBV- persons from a multiplicative effects model developed by JECFA 1998 20, as we 
previously did in the global cancer risk assessment, and we calculated the disease burden in 
different decades in the area. Next, we applied the aflatoxin potency factors, from an additive 
effects model of the aflatoxin and HBV infection in inducing liver cancer 170, and compared the 
estimated liver cancer burden with the results from multiplicative model for the same area in the 
same decade years.  
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Table 6. Variables to be considered in the validation analysis 
Possible key variables Quantifiable determinants Underlying 
determinants 
Average daily dietary 
aflatoxin intake 
• corn and peanuts consumption 
amount 
• aflatoxin contamination levels 
• bodyweight 
• gender difference 
(to be averaged) 
• detection limit of 
contamination 
Population • population growth rates age and gender 
distribution (to be 
standardized) 
Chronic HBV prevalence • vaccination rates gender and age difference 
(to be averaged) 
Potency factor of aflatoxin • multiplicative effects with 
HBV+ 
• additive effects with HBV+ 
The multiplicative effects 
model was developed 
from JECFA 1998 20; 
however, the aflatoxin 
potencies reflect additive 
effects were derived from 
a study conducted in 
2009 170. 
3.1.2 QUANTIFICATION OF THE POSSIBLE KEY VARIABLES IN THE MODEL 
Aflatoxin daily dietary intake 
Corn and peanut oil were confirmed to be the major source of dietary AFB1 exposure in 
Fusui County 54. Since the implementation of an HCC prevention program in Fusui from the 
1990s, local residents have gradually changed their main foods from corn to rice 171. As the 
results, a decline of AFB1 exposure in the local population was observed over the years.  Table 7 
summarized the changes of the diet style and the accordingly decreased AFB1 exposure. In 
1970s, almost 100% of daily food consumed by Fusui population was corn. 30 years later, the 
percentage of corn in total diet decreased to 48%, as more than half of daily food was replaced 
by rice.  
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Table 7. Aflatoxin B1 daily dietary intake in population of Fusui County, Guangxi, 
China, 1980s-2010s 
Year Corn consumed 
(g/day) 
Percentage of corn 
in daily food 
consumption (%) 
Peanut oil consumed 
per day (g/day) 
Aflatoxin B1 Exposure in 
study population from dietary 
food 
(ng/kg bw/day) 
1985 350-500 50 Almost 100% for average 50 Not available 
806 (men) 50 
1290 (women) 50 
967 (67-3683) for total AF 54 
1999 575  men 322 women 172 
76% for men, 
73% for women 145 18g
145 233 (men) 133 (women) 145 
2010 250 (75-500) 173  48% in average 173 7g 173 45(17–242)  173   
 
HBsAg+ prevalence and liver cancer incidence 
To control the endemic hepatitis B in the country, the Chinese government has 
implemented infant vaccination with hepatitis B vaccine from 1992, with the first dose to be 
administered within 24 h of birth and subsequent doses at 1 and 6 months 174. Indeed, a pilot 
study of the universal HBV vaccination program was initiated in 1986 in Long An county, 
located 90 miles away from Fusui, Guangxi province, and then spread to several other areas of 
China 175. It consisted of routine immunization services to all newborns in those areas in order to 
investigate the efficacy of vaccination. in Long An county, it was reported that the HBsAg 
positive rate was 16.5% in 1985 and 7.5% in 2005 175. However, the most significant decrease 
was observed in generation < 20 yr old, who received the vaccination at the birth. Chronic HBV 
infection is still endemic in generations between 20 to 65 years old in the area. Table 8 listed the 
HBsAg prevalence and liver cancer incidence data in Fusui, from 1980s to 2010s. The HBsAg 
positivity prevalence in Fusui population, as of in 2000s, decreased more than a half compared to 
it was in 1980s, while the liver cancer incidence only decreased slightly.  The discrepancy 
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between the declining HBsAg positive rates and the liver cancer incidence reflect the cancer 
latency factor, which means it will take 20-30 years to see the real benefit of reducing liver 
cancer incidences by vaccination program, because most of the HCC cases occur at age of 20 to 
65 in China. 
Table 8. Population, HBsAg prevalence and liver cancer incidence in Fusui, 
Guangxi, China, 1980s -2010s 
Decades Population  HBsAg positive 
(%)  
Age-standardized liver cancer incidence 
(per 100,000/yr) 
1980s 366,000 23.3% in men 176 120 in men, 31 in women 30 
1990s 403,000 29% 171 92-97 in men 171 
2000s 442,000 10.6 % 177 109 in male, 27 in female 178 
 
Aflatoxin potency factors 
Most of the observational studies revealed significant synergistic interactions between 
aflatoxins and chronic HBV infection in relation to liver cancer, with more than multiplicative 
effect being reported. In 1998, JECFA estimated aflatoxin potencies based upon the 
multiplicative effects, with 0.01 (0.002-0.03) cancers/year/100,000 per ng aflatoxin/kg bw per 
day in HBsAg- individuals and 0.3 (0.05-0.5) cancers/year/100,000 per ng aflatoxin/kg bw per 
day in HBsAg+ individuals 20. However, in a recent follow-up of the cohort in Taiwan with more 
HCC cases, Wu et al 170 reported the combined effects of AFB1 and HBV was consistent with an 
additive model rather than the multiplicative one. To evaluate how the inputs of potencies would 
affect the aflatoxin-attributable cancer burden, we estimated that the aflatoxin potency in 
HBsAg+ inviduals will be 0.1 cancers/year/100,000 per ng aflatoxin/kg bw per day, based upon 
the additive effect suggested by Wu et al. 
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3.2 RESULTS 
The estimated liver cancer incidences and cancer burden attributable to aflatoxin for 
Fusui County, Guangxi, China from 1980s to 2010s were calculated. Results were presented 
Table 9 and 10. In 1980s, we estimated 103 liver cancer cases per 100, 000 HBsAg male carriers 
and 11 cases per 100, 000 HBsAg male non-carriers per year would be attributable to aflatoxin 
exposure in Fusui. 27% of the total liver cancer cases occurred in males of Fusui in 1980s could 
be related to aflatoxin exposures, according to the actual disease burden  of 120 cases/100,000 in 
males. In contrast, under an additive effects model, 34 liver cancer cases per 100,000 HBsAg 
male carriers and 11 per 100,000 HBsAg male non-carriers per year were estimated to be 
attributable to aflatoxin, in 1980s in Fusui. Under additive model, 13% of the total liver cancer 
burden in males could be related to aflatoxin exposures in food. 
 In 1990s, the estimated HCC cases burden in males attributable to aflatoxin decreased to 
28 (15%) under a multiplicative model, and it would be 13 cases (7%) under an additive model. 
In 2000s, the estimated HCC cases attributed to aflatoxin continued to drop to 11 (4%) under the 
multiplicative model and 2 (0.7%) under the additive model. However, the wide range reflected 
the variation of the estimates of dietary aflatoxin exposure in the local population solely relying 
on food data. In high exposed individuals, the liver cancer burden attributable to aflatoxin could 
still go up to 19% (under multiplicative model). 
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Table 9. Estimated liver cancer incidences attributed to aflatoxin in Fusui, China 
Decades Population Estimated HCC cases attributed to 
aflatoxin, HBsAg- 
(per 100,000/yr) 
Estimated HCC cases attributed to 
aflatoxin, HBsAg+ 
(per 100,000/yr) 
Multiplicative 
effects model 
Additive effects 
model 
Multiplicative 
effects model 
Additive effects 
model 
1980s 366,000 11 in men 11 in men 103 in men 34 in men 
1990s 403,000 3 in men, 2 in  
women 
3 in men, 2 in 
women 
41 in men, 23 in 
women 
14 in men, 8 in 
women 
2000s 442,000 2 (1-10) 2 (1-10) 6 (2-35) 2 (1-11) 
 
Table 10. Estimated HCC burden attributed to aflatoxin in Fusui, China a 
Decades Actual liver 
cancer cases b  
(per year) 
Estimated HCC burden 
attributed to aflatoxin per year, 
multiplicative effects model 
N (%) 
Estimated HCC burden attributed 
to aflatoxin per year, additive 
effects model 
N (%) 
1980s 220 in males 59 in males (27%) 29 in males (13%) 
1990s 185-195 in males 28 in males (15%) 13 in males (7%) 
2000s 241 in males, 60 
in females 178 
11 (5-56)  
4% (2-19%) 
2 (1-10) 
0.7% (0.3 – 3%) 
(aAssuming 50% of the population is male, b calculated from the actual liver cancer incidence in 
Fusui County) 
3.3 DISCUSSION 
The risk assessment model we applied to estimate the aflatoxin-attributable liver cancer 
burden can be considered as a prediction model. The estimated burden of disease will actually 
reflect the situation in the next 15-40 years following the epidemiological and food data were 
collected, which is the latency time for a patient with chronic hepatitis to progress to liver cancer. 
That is to say, the estimated aflatoxin-attributable liver cancer cases based upon the data of 
dietary aflatoxin exposure, chronic HBV infection rates and the local population in 1980s, will 
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be the aflatoxin-attributed cancer burden of Fusui County in 2000 -2020. Indeed, the 27% of 
liver cancer burden attributed from aflatoxin calculated on the basis of data from 1980s, was 
confirmed by the population attributable risk fraction of liver cancer from aflatoxin in a Guangxi 
study 179 conducted in 2000s, calculated by another approach described in Chapter 4.  
In this validation analysis, the reduction of estimated aflatoxin-related liver cancer burden 
in Fusui, based upon data obtained  for 1980s and 1990s, reflected the benefits of reduced dietary 
aflatoxin exposure in population (because the HBsAg+ prevalence remained almost the same in 
two decades). By changing the diet style from almost 100% to 75% corn, and reducing the 
aflatoxin contamination level in corn (from 120 ppb to 24 ppb 54,145), the aflatoxin exposure for 
the local population was reduced 70-90% in 10-20 years. As a result, the estimated aflatoxin-
attributed liver cancer burden dropped about 50%.   
The reduction of estimated aflatoxin-related liver cancer burden in Fusui, based upon 
data obtained for 1990s and 2000s, reflected the benefits of both HBV vaccination and the 
reduced dietary aflatoxin exposure. By reducing the HBsAg+ prevalence from 29% in 1990s to 
11% in 2000s, and at the same time, further reducing 70-80% of the aflatoxin exposure in local 
population, the estimated aflatoxin-attributed liver cancer burden dropped about 70%.  
A lower estimated aflatoxin-attributed liver cancer burden under the additive model was 
observed when compared to the results from multiplicative model. However, the estimates from 
multiplicative model were close to the estimated results from a second approach based upon a 
study conducted in Guangxi, 2008 179 (see Chapter 4). This indicates a better defined model of 
combined effects in multiplicative relationship between aflatoxin exposure and chronic HBV 
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infection, compared to additive model. However, a comprehensive, systematic review of the 
epidemiological studies is needed to examine the model of combination effects.  
Overall, using the proposed risk assessment model, the estimated aflatoxin-attributable 
HCC cases in Fusui County in three decades were well within the actual disease burden of the 
local population. The numbers reflected reasonable percentages of the total incident HCC cases 
in different time period. This fact validated that the risk assessment model is a reliable tool to 
estimate the general HCC burden attributable to aflatoxin exposure, although the wide range 
around the estimates and the factor of cancer latency should be noted when the results are 
interpreted.  
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4.0  POPULATION-ATTRIBUTABLE RISK OF LIVER CANCER FROM 
AFLATOXIN EXPOSURE: A SYSTEMATIC REVIEW AND META-
ANALYSIS 
We previously reported an estimate of global burden of HCC attributable to aflatoxin. By 
compiling food consumption data and aflatoxin contamination data in various countries and 
regions, we estimated that 25,200-155,000 HCC cases worldwide, or 5-28% of all HCC cases, 
can be attributable to dietary aflatoxin 180. However, the large range of the reported estimate 
reflects the limitations in acquiring accurate exposures solely from food consumption data, 
uncertainties in the nature of the dose-response curve, uncertainties in the mode of interation 
between aflatoxins and viruses, and incomplete data on the prevalence of HBV in different 
regions of the world.  
In this context, the risk estimates of HCC from aflatoxin exposure presented as odds 
ratios, from population-based studies in which biomarkers of aflatoxin exposure and effect were 
measured will be helpful to address this knowledge gap. Furthermore, combining data from all 
eligible studies by meta-analysis has the advantage of reducing random error and obtaining more 
precise estimates of the association between the aflatoxin exposure, HBV infection and the HCC 
risk. Therefore, in this study, we systematically reviewed cohort or case-control studies in 
different world regions with reported odds ratios (ORs) or relative risks (RRs) of aflatoxin in 
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relation to liver cancer. By combining the relevant odds ratios (ORs) and relative risks (RRs) 
from these studies, we conducted meta-analyses to calculate population-attributable risk (PAR) 
of aflatoxin-related HCC in the population overall, as well as in HBV+ and HBV- populations. 
The meta-analysis also allowed us to compute the combined ORs of HCC from combined effects 
of dietary aflatoxin and HBV+, from aflatoxin only and from HBV+ only, and to determine the 
mode of interaction effects between two risk factors. In the context of our study, PAR of 
aflatoxin-related HCC is the proportion of HCC cases that could be avoided in a chosen 
population by reducing aflatoxin exposures (as measured by biomarkers) from detectable to 
undetectable levels. 
4.1 METHODS 
4.1.1 SEARCH STRATEGY AND STUDY ELIGIBILITY CRITERIA 
We performed a literature search to May 13th, 2011, using the Medline/PubMed 
databases without restrictions using the following search terms: (aflatoxin) and (hepatitis B) and 
(liver cancer); (aflatoxin) and (hepatitis B) and (hepatocellular carcinoma). Additionally, we 
searched the reference lists from retrieved articles to identify further potentially relevant studies. 
This systematic review was planned, conducted and reported in adherence to PRISMA standards 
for reporting meta-analyses 181-182.  
 
50 
 
Studies were included in the systematic review if they met the following criteria: (1) 
case-control or cohort study design; (2) aflatoxin as the exposure of interest, measured by 
biomarkers and/or food surveys; (3) HBV as the viral infection of interest (HBsAg positivity as a 
marker of chronic HBV infection); (4) HCC as the outcome of interest; and (5) RR or OR 
estimates with 95% confidence intervals (CIs) (or data to calculate these) reported. If data were 
duplicated (same study cohort and same period) in more than one eligible study, we included the 
study with validated biomarkers or enough quantitative measurements of the association between 
aflatoxin exposure and liver cancer. If more than one article reported results of a study from 
different perspectives, such as follow-up in different time periods (at least 5 years apart) or 
different target populations (HBsAg+ individuals only vs. general population), we treated these 
articles as different studies and included them all. 
4.1.2 DATA EXTRACTION 
The following data were extracted from each study: authors, publication year, study 
design and sample size, study location, study period, participants’ gender and age range, metric 
and range of aflatoxin exposure, estimated adjusted RRs/ORs, and variables adjusted for 
analysis. Because all identified studies are case-control designs except one cohort study, and 
because RR and OR can be used interchangeably when the disease is relatively rare (<15%; HCC 
rates are lower than this in the populations studied), we combined the RR from this study with 
the ORs from the case-control studies to calculate a summary OR. If aflatoxin exposure was 
measured using different biomarkers in the same study, we selected the ones reflecting consistent 
biomarkers amongst different studies (one OR per study was used).  
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4.1.3 STATISTICAL METHODS FOR META ANALYSIS 
The ORs from the studies were first combined in a meta-analysis using a random-effects 
model, and then a fixed-effects model if heterogeneity in the study pool was insignificant 183. 
The studies were categorized by the recruited population type: general populations, and HBV+ or 
HBV- populations. First, all the studies providing data for general populations (including both 
HBV+ and HBV- individuals) were combined, and ORs of aflatoxin-related HCC after HBsAg+ 
adjustment and ORs for combined (aflatoxin+HBV) effects were analyzed. Then the studies with 
data from HBV+ populations (and studies that recruited from the general population but 
separately estimated ORs in HBV+ populations) were combined; and the ORs for HBV+ 
populations only were estimated. We also combined the studies that separately estimated the 
ORs in HBV- populations. If the study examined the association between aflatoxin exposure and 
HCC in various exposure categories, we chose the ORs reflecting highest and lowest levels of 
aflatoxin exposure for the meta-analysis.  
Heterogeneity amongst the studies was evaluated using the Cochran’s Q value calculated 
from the Mantel-Haenszel method and the I² statistic 183. We performed sensitivity analyses in 
which each study was in turn removed and the rest analyzed to evaluate if the results were 
significantly affected by one particular study. Publication bias was assessed by a funnel plot and 
associated statistical tests of asymmetry. All statistical analyses were performed with 
Comprehensive Meta-Analysis software Version 2.2. 
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4.1.4 STATISTICAL METHODS FOR PAR CALCULATIONS 
We estimated PAR for aflatoxin-related HCC in two groups: 1) HBsAg- individuals, and 
2) HBsAg+ individuals, within each study if the data were available. To estimate the PAR for 
aflatoxin-related HCC using the adjusted RRs or ORs, we used an attributable fraction 
calculation formula described by Eq. 1 184: 
, 
where  is aflatoxin attributable risk fraction in the population including exposed 
and unexposed individuals, Pi is the proportion of the population in stratum i that is exposed, and 
Wi is the proportion of diseased individuals (cases) in stratum i. RRi is the adjusted RR or OR in 
stratum i. The weighted attributable risk fraction was calculated for aflatoxin in HBsAg+ and 
HBsAg- groups. We use adjusted ORi in stratum i as an approximation of RRi. 
If the study assessed the quantitative relationship between aflatoxin and HCC risk at 
different exposure levels, an overall attributable fraction was calculated by summarizing the AF 
across different exposure levels. If the study did not evaluate the association between aflatoxin 
and liver cancer risk stratified by HBsAg positivity but provided the risk estimates adjusted by 
HBsAg positivity, we then use the calculation formula Eq. 2 below 184 to estimate the PAR of 
aflatoxin in related with liver cancer in general population adjusted by HBsAg positivity: 
AFpop= RR
)1RR(P −c
 Eq. 2,
 
where Pc is the proportion of cases exposed in the combined population based on 
detection limits for aflatoxin biomarkers in the studies, and HBsAg positivity-adjusted OR is 
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used as an approximation of RR. For each AFpop, we calculated confidence intervals using the 
method described in Daly 185. 
 
4.2 RESULTS  
 
4.2.1 LITERATURE SEARCH 
The step by step process of our literature search is presented in Figure 3. From 479 
results, we excluded human cell line studies, animal studies, review articles, and studies without 
available abstracts. We read the titles and/or abstracts of all the remaining studies and chose the 
ones that investigated the association between aflatoxin (by biomarker or by food survey) and 
liver cancer risk. Any case-control, nested case-control and cohort studies for adults (>18 yrs) 
were included for this analysis provided that they met the criteria described above. 27 studies 
were thus selected. We also identified 3 relevant studies from the reference lists of the 27 
selected studies. We then read the full text of these 30 studies to determine 1) if the authors 
provided quantitative measurements of the association between aflatoxin exposure and HCC risk, 
2) if they analyzed the association between aflatoxin and HCC risk in HBV+ and HBV- 
individuals separately, 3) if HBsAg positivity was taken into consideration when the overall risk 
estimates were provided for the general population, and 4) if the individual articles were 
duplicated reports for one study population or they were follow-up studies after the first initiated 
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study. Six studies were excluded because they were duplicated reports from the same population 
in the same time period, and 7 studies were excluded because the quantitative measurements of 
association between aflatoxin exposure and HCC with HBsAg+ adjustment were not provided in 
the text. Thus, 17 studies were included for this systematic review and PAR analysis.  
 
 
Figure 3. Selection of studies for inclusion in systematic review 
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4.2.2 STUDY CHARACTERISTICS  
Table 11 provides an overview of the eligible studies, including the study year, the study 
population and sample size, the biomarker measured in the study, and the adjusted RRs or ORs 
for aflatoxin-related HCC provided by these studies.  
The 17 studies 5-8,56-58,170,179,186-193 on aflatoxin exposure and liver cancer risk - 8 case-
control studies, 8 nested case-control studies, 1 cohort study - were published between 1994 and 
2009. There were 1680 HCC cases and 3052 controls in total. All the eligible studies were 
conducted in areas of the world where aflatoxin exposure was relatively high in the diet (until 
recently): China, Taiwan, and sub-Saharan Africa. 6 studies were conducted in China, 7 in 
Taiwan and 4 in sub-Saharan Africa. 14 out of 17 studies reported biomarker measurements for 
aflatoxin exposure, while the other 3 studies relied on food consumption data. Among the 14 
studies that utilized biomarkers to measure aflatoxin exposure, 5 studies measured urinary 
aflatoxin biomarkers, including AFM1 and AFB1-N7-Gua, 6 studies measured AFB1-albumin 
adducts, 2 studies measured AFB1-DNA adducts, and 3 studies measured TP53 249ser mutation 
as the biomarker(s) of interest. Several studies included measures of more than one biomarker.  
12 studies were conducted in both HBsAg+ individuals and non-individuals, with risk estimates 
that were adjusted for HBsAg positivity (9 studies), age (6 studies), gender (4 studies), tobacco 
smoking (4 studies), alcohol consumption (3 studies), anti-HCV (3 studies), and family liver 
disease history (3 studies). 5 studies were conducted in HBsAg+ individuals only, and the risk 
estimates were adjusted for cigarette smoking (2 studies), alcohol drinking (2 studies), age (2 
studies) and gender (1 study).  
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Four studies reported results for one Taiwanese cohort from four different time 
periods7,170,186,192 from 1980s to 2000s. To determine if all these studies should be included in the 
meta-analysis, we first examined the heterogeneity between the risk estimates provided by these 
studies. Because of the significant heterogeneity of aflatoxin exposures and HCC risk estimates 
in this cohort between the follow-up studies through the years, we treated these as independent 
studies in the analysis. In analyses that included only the most recent of all studies in a particular 
cohort, the results were nearly identical to those obtained when including all studies (Table 13). 
Two articles reported results from one case-control study in Sudan from different perspectives 
(risk estimates for the general population after adjustment of HBsAg+, and risk estimates for 
HBsAg+ or HBsAg- separately) 8,191. Likewise, two articles reported results from a study in The 
Gambia with risk estimates for the general population after adjustment of HBsAg+, and risk 
estimates for HBsAg+ or HBsAg- separately 5,190.   
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Table 11. Characteristics of the eligible studies included in the systematic review / meta-analysisiv,v 
No Source Location/ period Sex 
Age, 
yrs 
No of Cases 
 (% exposed) 
No of Controls 
(% exposed) 
Measure/Range of Exposure, 
detection limit 
Adjusted 
ORs/RRsvi 
Adjustment for 
Covariates 
1 
Qian et al., 1994 6 
(cohort of 18,244 
middle-aged men) 
China, 
1986-
1992 
M 45-64 
50 cases (36%) 267 matched controls (12%) 
AFB1-N7-Gua adduct 
 (detectable vs non-detectable, 
0.07ng aflatoxins/ml urine 
9.1 (2.9-29.2) 
HBsAg positivity, 
cigarette smoking 
50 cases (72%) 
267 matched 
controls 
(41%) 
Multiple urinary biomarker 
(detectable vs non-detectable, 
0.01fmol/µg) 
5.0 (2.1-11.8) 
2 
Chen et al., 1996 
186 
(7 township cohort 
nested case-control 
study) 
Taiwan, 
1991-
1992 
F/M 36-65 20 cases (65%)  
86 matched 
controls 
(37%) 
AFB1-albumin adducts 
(detectable Vs non-detectable, 
0.01fmol/µg) 
5.5 (1.2-24.5) 
HBsAg, anti-HCV, 
family history of liver 
cancer 
cirrhosis 
3 
Chen et al., 1996 
187 
(nested case-
control in cohort of 
4,841 male HBsAg 
individuals) 
Taiwan, 
1988-
1992 
M 30-65 
32 cases (37.5% 
low exposure) 
73 matched 
controls 
(33% low 
exposure) 
AFB1-albumin adducts 
(Low Vs Non-detectable, 
0.01fmol/µg) 
1.6 (0.6-4.0) 
Cigarette smoking, 
alcohol consumption 
32 cases (19% 
high exposure) 
73 matched 
controls 
(6.8% high 
exposure) 
AFB1-albumin adducts 
(High Vs Non-detectable, 
0.01fmol/µg) 
3.8 (1.0-14.5) 
4 
Wang et al., 1996 7 
(7 township cohort 
nested case-control 
study 
Taiwan, 
1991-
1995 
F/M 30-64 
52 cases (60%) 
168 matched 
controls 
(37%) 
AFB1-albumin adducts 
(detectable vs non-detectable, 
0.01fmol/µg) 
1.6 (0.4-5.5) 
HBsAg positivity 
38 cases (53%) 
137 matched 
controls 
(45%) 
Urinary aflatoxin metabolite 
(high vs low, 0.01fmol/µg) 3.8 (1.1-12.8) 
                                                 
iv All the eligible studies were conducted in China (6), Taiwan (7), or sub-Saharan Africa (4). Fourteen studies reported biomarker measurements for aflatoxin 
exposure, while the other three studies relied on food consumption data. Twelve studies included both HBsAg+ and HBsAg- individuals, with risk estimates that 
were adjusted for HBsAg positivity (nine studies). Five studies were conducted in HBsAg+ populations only. 
v Among the fourteen studies that utilized biomarkers, five measured urinary aflatoxin biomarkers, including AFM1 and AFB1-N7-Guanine, six measured AFB1-
albumin adducts, two measured AFB1-DNA adducts, and three measured TP53 249ser mutations. Several studies included measures of more than one biomarker.   
vi 15 out of 16 identified case-control studies provided matched ORs.  
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5 
Zhang et al., 1997 
189 
(Hospital-based 
case-control study) 
 
China,  
1994-
1995 
F/M 18-88 
152 cases (33%) 
115 non-hepatic 
patient controls 
(2%) 
Corn consumption history from 
dietary questionnaire 
(1:1 pair-
matched) 
16.44 (1.67-
61.65) 
HBV infection, 
individual history of 
liver diseases, family 
history of liver diseases, 
and peanut consumption 
152 cases (89%) 
115 non-hepatic 
patient controls 
(49%) 
Peanut consumption history from 
dietary questionnaire 3.51(1.45-8.47) 
HBV infection, 
individual history of 
liver diseases, family 
history of liver diseases, 
and corn consumption 
6 
Yu et al., 1997 188 
(nested case-
control of a cohort 
of 4841 male 
HBsAg 
individuals) 
Taiwan, 
1988-
1994 
M 30-65 
42 cases (29%) 
43 matched 
controls 
(14%) 
AFB1-N7-gua, 
(below 0.21 ng/ml Vs 0.21-0.36 
ng/ml, 0.05 ng aflatoxin/ml urine) 
5.3(1.1-25.2) 
Education level, 
ethnicity, habitual 
alcohol drinking and 
cigarette smoking status 
42 cases (14%) 
43 matched 
controls 
(16%) 
AFB1-N7-gua 
(below 0.21 ng/ml Vs >0.36 
ng/ml, 0.05 ng aflatoxin/ml urine) 
2.8 (0.6-12.9) 
42 cases (24%) 
 
43 matched 
controls 
(23%) 
AFM1 
(below 1.61 ng/ml Vs 1.61-2.85 
ng/ml, 0.05 ng aflatoxin/ml urine) 
1.9(0.5-7.2) 
42 cases (55%) 
43 matched 
controls 
(35%) 
AFM1 
(below 1.61 ng/ml Vs >2.85 
ng/ml, 0.05 ng aflatoxin/ml urine) 
6.0(1.2-29.0) 
7 
Lunn et al., 199757 
(case-control 
study) 
Taiwan, 
1984-
1995 
F/M  105 cases (80%) 37 controls (43%) AFB1-DNA adducts 
Corrected OR: 
3.9(1.4-11.5) 
 
n/a 
8 
Kirk et al., 2000 190 
(case-control 
study) 
 
The 
Gambia, 
1997-
1998 
F/M 20-73 53 cases (36%) 
53 matched 
controls 
(5.7%) 
Ser-249 P53 mutation 16.4 (3.0-90.5) 
Age, sex, recruitment 
site and HBsAg 
positivity 
9 
Sun et al., 2001 192 
(7 township cohort 
nested case-control 
study, HBsAg 
individuals) 
Taiwan, 
1991-
1997 
F/M 30-64 75 cases (64%) 140 matched controls (46% ) 
Aflatoxin-albumin adducts 
(detectable vs non-detectable, 
0.01fmol/µg) 
2.0 (1.1-3.7) Sex, age and residence 
10 
Omer et al., 
2001191  
(case-control 
study) 
Sudan  
1996-
1998 
F/M 20-70 115 cases 199 matched controls 
Peanut butter consumption 
>300 g/mo 
Vs 
Peanut butter consumption <70 
g/mo 
3.3(1.4-8.1) Age and hepatitis 
Table 11 continued 
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11 
Ming et al., 2002 
193 
(Hospital-based 
cohort, 145 
HBsAg individuals 
) 
Qidong, 
China M 27-74 31 cases 
145 HBsAg+ 
carriers follow up 
AFM1 
(>3.6 ng/l) 3.5(1.5-8.1) 
Age, HCV, family 
history of HCC 
12 
Huang et al., 2003 
56 
(case-control 
study) 
Qidong, 
China F/M 19-87 25 cases (40%) 30 controls (6.7%) Ser 249 TP 53 mutation 22.1(3.2-91.7) 
Sex, age, recruitment 
site and HBsAg 
positivity 
13 
Omer et al., 2004 8 
(case-control 
study) 
Sudan,  
1996-
1998 
F/M 20-70 114 cases (46%) 198 matched controls (26%) 
Peanut butter consumption 
>300 g/mo 
Vs 
Peanut butter consumption <70 
g/mo 
n/a age 
14 
Kirk et al., 2005 5 
(case-control 
study) 
Gambia, F/M  186 cases (40%) 348 matched controls (3.4%) Ser-249 TP53 mutation 20.3 (8.19-50.0) 
Adjusted for study 
group, season of 
recruitment and daily 
groundnut intake 
15 
Long et al., 2009 
179 
(hospital-based 
case-control) 
China,  
2006-
2008 
F/M 
12.1% 
<35, 
77.8% 
35-65, 
10.1% 
>65 
618 cases (28%) 712 matched control (29%) 
AFB1-adduct: Low (≤ 1·00 
µmol/mol DNA) Vs  Medium 
(1.01-2.00 µmol/mol DNA), 
(0.25µmol/mol DNA) 
2.11 (1.54-2.90) 
 Age, sex, ethnicity, 
HBsAg, anti-HCV, and 
AFB1 –exposure years 
618 cases (47%) 712 matched controls (17%) 
AFB1-adduct: 
Low (≤ 1.00 µmol/mol DNA) Vs 
High (≥2.01 µmol/mol DNA) 
(0.25µmol/mol DNA) 
6.23 (4.48-8.67) 
16 
Wu et al., 2009 170 
(7 township cohort 
nested case-control 
study) 
Taiwan 
1991-
2004 
F/M 30-64 yr 
230 cases (93%) 
1052 matched 
controls 
(95%) 
AFB1-albumin adduct(fmol/mg): 
Non-detectable Vs Detectable 
(0·01fmol/µg or 1fmol/ml) 
0.99 (0.48-2.02) 
HBsAg, anti-HCV, 
habitual smoking, 
alcohol drinking, BMI 
and the batch of 
aflatoxin biomarker 
assay 
230 cases (33%) 
1052 matched 
controls 
(33%) 
AFB1-albumin adduct(fmol/mg): 
Below the mean (<59·8) Vs. 
Above the mean (≥59·8),  
1.54 (1.01-2.36) 
198 cases (88%) 
904 matched 
controls 
(88%) 
Urinary AFB1 metabolites 
(fmol/ml): Non-detectable Vs 
Detectable 
(0.01fmol/µg or 1fmol/ml) 
1.70 (0.89–3.25) 
198 cases (57%) 904 matched controls (44%) 
Urinary AFB1 metabolites: Below 
the mean Vs Above the mean 1.76 (1.18-2.58) 
Table 11 continued 
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17 
Szymanska et al., 
2009 58 
(nested case-
control study) 
China, 
 1989-
1998 
M 30-59 126 cases (67%) 123 matched controls (68%) 
AF-albumin 
Detectable Vs non-detectable 
(3 pg/mg) 
0.90 (0.52-1.56) In HBV individuals 
Table 11 continued 
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4.2.3 RISK ESTIMATES FOR CALCULATION OF PAR OF AFLATOXIN-RELATED 
LIVER CANCER  
To assess the effect of aflatoxin exposure on the relationship between HBV infection and 
HCC, data from eligible studies were extracted and stratified into two groups based on HBsAg 
status.  Risk estimates of aflatoxin-related HCC in HBsAg+ and HBsAg- groups were calculated 
separately. Twelve studies estimated the overall ORs in the combined populations. Among them, 
six studies provided risk estimates in HBsAg+ and HBsAg- groups separately, while five studies 
provided risk estimates in HBsAg+ groups only. To analyze the population attributable risk of 
aflatoxin-related HCC in different studies, we calculated the percentage of exposed cases in the 
combined population (Pc) for eligible studies, the proportion of liver cancer cases in HBsAg+ 
groups (W1) and the proportion of study population in this stratum exposed to aflatoxin, which is 
obtained from the percentage of detectable biomarkers in the HBsAg+ group (P1), the proportion 
of liver cancer cases in HBV- group (W2), and the proportion of the study population in this 
stratum exposed to aflatoxin (P2). The results were presented in Table 12. We estimated the 
unadjusted ORs of aflatoxin in HBsAg+ group for those studies that did not stratify data by 
HBsAg positivity. Interestingly, the aflatoxin exposure prevalence was higher in HBsAg+ (P1) 
than HBsAg- (P2) individuals in 6 studies that analyzed the association in two groups separately. 
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Table 12. Risk estimates for calculation of liver cancer PAR from aflatoxin exposure from eligible studies 
References Exposure measurement 
Proportion of 
exposed cases 
(Pc) 
Proportion of 
HCC cases in 
HBsAg+ (W1) 
Proportion of 
aflatoxin 
exposed 
HBsAg+ (P1) 
Proportion of 
HCC cases in 
HBsAg- (W2) 
Proportion of 
aflatoxin 
exposed HBsAg- 
(P2) 
Adjusted 
RRs/ORs in 
HBsAg+ 
Adjusted 
RRs/ORs in 
HBsAg- 
Qian et al., 
19946 
urinary aflatoxin 
metabolites 36/(50+267)=0.114 32/63=0.51 30/63=0.48 18/254=0.07 115/254=0.45 
8.76(2.80-
27.4)a 
3.4 (1.1-
10.0) 
Chen et al., 
1996 187 
high AFB1-
albumin level vs 
non-detectable 
n/a 20/105=0.19 11/105=0.11 n/a n/a 3.8(1.0-14.5) n/a 
low AFB1-
albumin level vs 
non-detectable 
n/a 26/105=0.25 36/105=0.34 n/a n/a 1.6(0.6-4.0) n/a 
Chen et al., 
1996 186 AFB1-albumin 13/106=0.123 n/a n/a n/a n/a n/a n/a 
Wang et al., 
1996 7 
aflatoxin-
albumin 31/(52+180)=0.134 40/64=0.625 36/64=0.563 8/161=0.05 53/161=0.33 2.8 (0.9-9.0) 0.3 (0-3.6) 
urinary aflatoxin 
metabolite 26/(38+137)=0.149 29/50=0.58 27/50=0.54 6/120=0.05 57/120=0.475 
5.5 (1.3-23.4) 
 
1.7 (0.3-
10.8) 
Yu et al., 
1997 188 
0.21-0.36 ng/ml 
(AFB1-N7-gua vs 
non-detectable) 
n/a 36/86=0.42 18/86=0.21 n/a n/a 5.3 (1.1-25.2)  n/a 
> 0.36 ng/ml 
(AFB1-N7-gua vs 
non-detectable) 
n/a 30/86=0.35 13/86=0.15 n/a n/a 2.8(0.6-12.9)  n/a 
Lunn et al., 
1997 57 AFB1-DNA 84/(105+37)=0.59 79/88=0.90 67/88=0.76 26/54=0.48 33/54=0.61 
1.69 (0.39-
7.46)b 
17.4(3.4-
90.3) 
Zhang et 
al., 1998 189 
Corn 
consumption 
50/(152+115) 
=0.187 n/a n/a n/a n/a n/a n/a 
Peanut 
consumption 
136/(152+115)=0.5
09 n/a n/a n/a n/a n/a n/a 
Kirk et al., 
2000 190 
TP53 Ser 249 
mutation 19/(53+53)=0.179 n/a n/a n/a n/a n/a n/a 
Sun et al., 
2001 
192 
AFB1-albumin 
adducts n/a 75/215=0.35 111/215=0.52 n/a n/a 2.0(1.1-3.7) n/a 
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Omer et al., 
2001191 
Peanut butter 
consumption 
>300 g/month 
63/(85+104) =0.33 n/a n/a n/a n/a n/a n/a 
Ming et al., 
2002 193 AFM1 n/a 31/145=0.21 78/145=0.54 n/a n/a 3.5 (1.8-8.1) n/a 
Huang et 
al., 2003 56 
TP53 Ser 249 
mutation 10/(25+30)=0.182 n/a n/a n/a n/a n/a n/a 
Omer et al., 
2004 
8(Sudan) 
Peanut butter 
consumption 
>300 g/month 
53/(114+198)=0.17
0 29/38=0.76 30/38=0.80 38/131=0.29 74/131=0.56 
1.19 (0.21-
6.69)c 5.1(1.8-13.9) 
Kirk et al., 
2005 5 
TP53 Ser 249 
mutation 
74/(186+348)=0.13
9 99/146=0.68 46/146=0.32 84/382=0.22 39/382=0.10 
38.3 (5.08 – 
289)d 
13.2(4.99-
35.0) 
Wu et al., 
2009 170 
 
AFB1-albumin 
adducts 
(above the mean 
vs below the 
mean) 
75/(230+1052)=0.0
59 155/456=0.34 126/456=-0.28 75/826=0.09 293/826=0.35 
1.43(0.76-
2.71) 
1.65(0.63-
4.33) 
Urinary aflatoxin 
metabolites 
(above the mean 
vs below the 
mean) 
113/(198+904)=0.1
03 143/411=0.348 209/411=0.509 55/691=0.08 299/691=0.433 
1.19(0.72-
1.98) 
4.29(1.43-
12.85) 
Szymañska 
et al., 2009 
58 
AFB1-albumin 
adducts n/a 126/249=0.51 168/249=0.67 n/a n/a 
0.90 (0.52-
1.56) n/a 
Long et al., 
2009 
AFB1-DNA 
adducts medium 
vs low 
172/1330 = 0.129 n/a n/a n/a n/a n/a n/a 
AFB1-DNA 
adducts high vs 
low 
293/1330=0.220 n/a n/a n/a n/a n/a n/a 
(a,b,c,d, Risk ratio estimates were unadjusted.) 
Table 12 continued 
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4.2.4 AFLATOXIN EXPOSURE (DETECTABLE/HIGH VS. NON-
DETECTABLE/LOW) AND HCC RISK, ANALYSIS SEPARATED BY HBSAG+ 
STATUS AND GEOGRAPHIC LOCATION  
The association between aflatoxin exposure and liver cancer, independently or in 
conjunction with chronic HBV infection was analyzed from combining the eligible studies by 
HBsAg+ status and calculating the summary ORs (Table 13, forest plot Figure 4-7) in HBsAg+ 
individuals, HBsAg- individuals and general population. We also did meta-analysis for 
subgroups (China, Taiwan and Sub-Saharan Africa). In forest plot of figure 4 to figure 7, the 
squares and horizontal lines correspond to the study-specific OR and 95% CI; the box size is 
proportional to the meta-analysis study weight; the diamonds represent the combined OR and 
95% CI. In summary, aflatoxin exposure is significantly associated with HCC risk, regardless of 
HBsAg status, with a summarized OR of 4.75 (2.78-8.11) from nine studies in the general 
population adjusted by HBsAg positivity, 2.39 (1.50-3.82) from eleven studies in HBsAg+ 
populations and 5.91 (3.66-9.55) from six studies in HBsAg- populations.  
 
Aflatoxin Exposure and HCC Risk adjusted by HBsAg+ 
The adjusted (HBsAg positivity included) RRs/ORs for each study and all studies 
combined are shown in Figure 4. We combined nine studies which provided ORs adjusted by 
HBsAg positivity for analysis by the Comprehensive Meta-Analysis. Data from eight of these 
studies were eligible for the calculations. Other OR datasets were selected from the studies if 
associations were made using different biomarkers. When combining studies that provided a 
range of aflatoxin exposures, we chose the ORs corresponding to the highest and lowest 
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aflatoxin exposures in each study. The combined OR of HCC from the detectable/high vs. non-
detectable/low aflatoxin exposures (adjusted by HBsAg positivity) is 4.75 (95% CI: 2.78-8.11). 
The heterogeneity between the studies is significant (Q=32.73, P<0.000, I2=75.56). Because four 
out of the nine studies were a series of follow up studies from 1991 to 2004 as we previously 
described, we also analyzed the combined ORs by only including the most recent study Wu et 
al., published in 2009 and excluding the other three studies out of the pool. The recalculated 
combined OR of HCC from the detectable/high vs. non-detectable/low aflatoxin exposures 
(adjusted by HBsAg positivity) is 4.88 (95% CI: 2.69-9.10). The heterogeneity between the 
studies is still large (Q=32.55, P<0.000, I2=81.57). 
We also grouped the four follow up studies in Taiwan and taking the avergae effect of 
them to combine with studies from other areas. The recalculated combined OR of HCC from the 
detectable/high vs. non-detectable/low aflatoxin exposures (adjusted by HBsAg positivity) is 
4.92 (95% CI: 2.74-8.82). The heterogeneity between the studies is still large (Q=29.48, 
P<0.000, I2=79.65). 
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Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper Relative 
ratio limit limit Z-Value p-Value weight
Qian et al., 1994 5.000 2.109 11.852 3.655 0.000 12.18
Chen et al., 1996 5.500 1.217 24.852 2.215 0.027 7.37
Wang et al., 1996 3.800 1.114 12.963 2.132 0.033 9.20
Zhang et al., 1997 3.510 1.452 8.483 2.789 0.005 12.00
Huang et al., 2003 22.100 5.326 91.700 4.264 0.000 7.88
Kirk et al., 2000 16.400 2.986 90.076 3.219 0.001 6.35
Omer et al., 2001 3.300 1.372 7.938 2.666 0.008 12.05
Long et al., 2009 6.230 4.478 8.667 10.861 0.000 16.70
Wu et al., 2009 1.760 1.190 2.602 2.833 0.005 16.28
4.749 2.782 8.108 5.710 0.000
0.01 0.1 1 10 100
Favours A Favours B
Random Effect Model
 
Figure 4. Odds ratios of liver cancer risk for aflatoxin exposure (detectable/high vs. non-detectable/low), adjusted by 
HBsAg status
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Aflatoxin Exposure (Detectable vs Non-detectable) and HCC Risk in HBsAg+ Individuals 
There were seven studies reported adjusted RRs/ORs on aflatoxin-related HCC risk in 
HBsAg+ individuals, and four studies did not provide the adjusted ORs of aflatoxin and liver 
cancer in HBsAg+ directly but the unadjusted ORs could be obtained from the data provided. We 
calculated the unadjusted ORs of aflatoxin and liver cancer risk in HBsAg+ individuals for each 
of these studies and combined them with ORs from the other seven studies with eligible data. 
Thus, eleven studies were combined, and the combined OR of liver cancer for the 
detectable/high vs non-detectable/low aflatoxin exposure in HBsAg+ individuals was 2.39 (95% 
CI: 1.50-3.82) with substantial heterogeneity (Q=27.99, P=0.002, I2=64.27) (Figure 5). The 
analyses above included all follow-up studies within given study populations (described in 
previous paragraph). If only the most recent studies within each study population were included 
(Wu e al. 170 and Yu et al. 188), the OR was 2.27 (95% CI: 1.24-4.14). The heterogeneity among 
these studies is statistically significant (Q=24.33, P=0.001, I2=71.23). If we only combined 
studies with adjusted ORs, the combined OR was 2.10 (95% CI: 1.25-3.52) with Q=16.40, 
P=0.012, I2=63.42
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Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper Relative 
ratio limit limit Z-Value p-Value weight
Qian et al., 1994 2.80 1.55 5.05 3.42 0.00 13.35
Chen et al., 1996 3.80 1.00 14.47 1.96 0.05 7.09
Wang et al., 1996 5.50 1.30 23.33 2.31 0.02 6.46
Lunn et al., 1997 1.69 0.39 7.39 0.70 0.49 6.29
Yu et al., 1997 6.00 1.22 29.50 2.21 0.03 5.70
Sun et al., 2001 2.00 1.09 3.67 2.24 0.03 13.18
Ming et al., 2002 3.50 1.51 8.13 2.91 0.00 10.91
Omer et al., 2004 1.19 0.21 6.72 0.20 0.84 5.09
Kirk et al., 2005 38.30 5.08 288.88 3.54 0.00 4.06
Syzmanska et al., 2009 0.90 0.52 1.56 -0.38 0.71 13.73
Wu et al., 2009 1.19 0.72 1.97 0.67 0.50 14.14
2.39 1.50 3.82 3.66 0.00
0.01 0.1 1 10 100
Favours A Favours B
Random Effect Model
 
Figure 5. Adjusted odds ratios of liver cancer risk for the detectable/high vs. non-detectable/low aflatoxin exposure in 
HBsAg+ populations
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Aflatoxin Exposure (Detectable vs. Non-detectable) and HCC Risk in HBsAg- Individuals 
6 studies reporting RRs/ORs on aflatoxin exposure and liver cancer risk in HBsAg- 
individuals were combined. The reported RRs/ORs and the combined ORs are shown in Figure 
6. The combined OR of liver cancer for the detectable vs. non-detectable aflatoxin exposure in 
HBsAg- individuals is 5.80 (95% CI: 3.17-10.59).The heterogeneity among these studies is 
insignificant (Q=7.51, P=0.185, I2=33.42). We then assessed the association using fixed-effects 
model within this study pool because of the insignificant heterogeneity. The OR with fixed-
effects model is 5.91 (95%: 3.66-9.55). If we analyze the combined studies which only include 
the most recent follow up study in the Taiwan cohort, Wu et al., published in 2009 170, the OR 
will be 6.54 (95% CI: 3.62-11.82), The heterogeneity among these studies is insignificant 
(Q=5.51, P=0.24, I2=27.49).  
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Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper Relative 
ratio limit limit Z-Value p-Value weight
Qian et al., 1994 3.40 1.13 10.25 2.17 0.03 18.89
Wang et al., 1996 1.70 0.28 10.20 0.58 0.56 7.17
Lunn et al., 1997 17.40 3.38 89.67 3.41 0.00 8.56
Omer et al., 2004 5.10 1.84 14.17 3.12 0.00 22.03
Kirk et al., 2005 13.20 4.98 34.96 5.19 0.00 24.26
Wu et al., 2009 4.29 1.43 12.86 2.60 0.01 19.09
5.91 3.66 9.55 7.26 0.00
0.01 0.1 1 10 100
Favours A Favours B
Random Effect Model
 
 
Figure 6. Adjusted odds ratios of liver cancer risk for the detectable/high vs. non-detectable/low aflatoxin exposure in 
HBsAg- populations
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4.2.5 SENSITIVITY ANALYSIS 
For the meta-analysis of aflatoxin-related HCC risk in the general population, our 
sensitivity analyses revealed that Wu et al. 170 was the most influential study in determining the 
summarized OR. After excluding this particular study, heterogeneity was significantly reduced 
(Q=8.40, P=0.30, I2=16.66), and the summarized OR was 5.57 (3.78-7.79).  
For the meta-analysis of aflatoxin exposure and HCC in HBsAg+ populations, our 
sensitivity analyses showed that two studies, Szymanska et al. 58 and Wu et al. 170, substantially 
influenced the summarized OR. After excluding the two studies, heterogeneity was significantly 
reduced (Q=11.16, P=0.19, I2=28.29), and the summarized OR of HCC risk for detectable vs. 
non-detectable aflatoxin exposure in HBsAg+ individuals was 2.90 (2.09-4.01). These results 
suggest that the two studies that measured the association between HCC and aflatoxin exposure 
in the most recent years58,170 appear to have significantly different results from relatively earlier 
studies.  
For the 10 studies 6,7,56,57,170,179,186,189-191 associating aflatoxin and liver cancer in the 
general population, we assessed publication or other forms of selection bias by a funnel plot 
(Figure 8) and associated statistical tests of funnel plot asymmetry 194. Seven studies are not 
included in this plot; five studied the association in HBsAg+ individuals only, and two are 
duplicate studies included in meta-analysis for different data extraction purposes, as explained in 
the Methods. The funnel plot provides little evidence of an important departure from symmetry, 
indicating that publication or other forms of selection bias were not a serious limitation in our 
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meta-analysis. This visual impression of symmetry was corroborated by the statistical tests of 
funnel plot asymmetry. 
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Table 13. Summary of combined odds ratios in the meta-analysis 
Risk factor Study Population Study area (n of studies) Cases/controlsvii Odds Ratio, 95% CI Model Heterogeneity 
Aflatoxin only 
General population with 
HBsAg+ adjustment 
China (4) 6,56,179,189 634 cases/913 controls 5.99 (3.70-9.69) Fixed Q=4.86, P=0.18, I2=38.32 
Taiwan (3)viii 7,170,186 198 cases/904 controls 2.01 (1.40-2.89) Fixed Q=3.19, P=0.20, I2=37.29 
Sub-Saharan Africa (2) 
190,191  168 cases/252 controls 4.62 (2.12-10.08) Fixed Q=2·69, P=0·1, I
2=62·82 
Summary (9) 1000 cases/2069 controls 4.75 (2.78-8.11) Random Q=32.73, P<0·000, I2=75.56 
General population with 
HBsAg+ adjustment after 
adjust heterogeneity 
Summary (8) 5-8,56,179,186,189 840 cases/1302 controls 5.72 (4.42-7.40) Fixed Q=8.40, P=0.30, I2=16.66 
General population with 
HBsAg+ adjustment by 
only including Wu et al as 
follow-up for cohort in 
Taiwan 
Summary (7) 
5,6,8,56,170,179,189 1000 cases/2069 controls 4.88 (2.62-9.10) Random Q=32.55, P<0.000, I
2=81.57 
General population with 
HBsAg+ adjustment by 
taking the average effect 
of the series of Taiwan 
Studiesix 
Summary (7) 1000 cases/2069 controls 4.92 (2.74-8.82) Random Q=29.48, P<0.000, I2=79.65 
HBsAg+ individuals 
China (3) 6,58,193 189 cases/268 controls 2.00 (0.84-4.75) Random  Q=10·66, P=0·005, I2=81·24 
Taiwan (6) 7,57,170,187,188,192 254 cases/310 controls 1.81(1.29-2.56) Fixed Q=8.38, P=0.14, I2=40.35 
Sub-Saharan Africa (2) 5,8 128 cases/56 controls 6.48 (0.22-194) Random  Q=6.54, P=0.01, I2=84.71 
Summary (11)x 571 cases/634 controls 2.39 (1.50-3.82) Random Q=27.99, P=0.002, I2=64.27 
                                                 
vii If there was a series of follow-up studies in the same cohort need to be combined, only the numbers of cases and controls from the largest follow-up study were 
counted, although different odds ratios from different follow-up studies were combined to assess the effect. All the cases and controls were only counted once, 
and as well as in calculations presented in Table 4 and 5. 
viii This row shows the summary odds ratio of combing three follow-up studies in a Taiwan cohort in different years 
ix The summary odds ratio obtained for the Taiwan cohort was used to represent the effect of all studies in this cohorts, and combine with other studies 
x Seven studies (7, 15, 17, 21-22, 25-26) reported adjusted ORs on aflatoxin-related HCC risk in HBsAg+ individuals. Four studies (5-6, 8, 16) (including two 
studies conducted in Sub-Saharan Africa countries) did not provide adjusted ORs directly, but provided data to calculate the unadjusted ORs. We calculated the 
unadjusted ORs for each of these studies and combined them with ORs from other studies with eligible data, thus we can include the effects of studies in Sub-
Saharan Africa population. In subgroup analysis, the large variation of summarized ORs of aflatoxin-related HCC in HBsAg+ individuals may be explained by 
combining the unadjusted ORs. The heterogeneity was significant when studies were combined to examine the association between aflatoxin exposure and HCC 
risk in the general population and in HBsAg+ individuals.  
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HBsAg+ individuals after 
adjust heterogeneity 
Summary (9) 5-
8,57,187,188,192,193 377 cases/383 controls 2.90 (2.09-4.01) Fixed Q=11.16, P=0.19, I
2=28.29 
HBsAg+ individuals by 
only including most recent 
follow-up studies in a 
cohort of Taiwan 
Summary (8) 
5,6,8,57,58,170,188,193 571 cases/634 controls 2.27 (1.24-4.14) Random Q=24.33, P=0.001,  I
2=71.23 
HBsAg+ individuals by 
only combing studies with 
adjusted ORs 
Summary 332 cases/538 controls 2.10 (1.25-3.52) Random Q=16.40, P=0.012, I2=63.42 
HBsAg+ individuals by 
taking the average effect 
of all follow-up studies in 
the same cohort xi 
Summary (8) 571 cases/634 controls 2.35(1.38-3.99) Random Q=23·17, P=0·002,  I2=69.79 
HBsAg- individuals 
China (1) 6 18 cases/ 236 controls 3·4 (1·13-10·25)  / / 
Taiwan (3) 7,57,170 81 cases/664 controls 5·00 (2·22-11·28) Fixed  Q=3·69, P=0·16, I2=45·79 
Sub-Saharan Africa (2) 5,8 122 cases/391 controls 8·40 (4·15-16·99) Fixed Q=8·40, P=0·19, I2=42·63 
Summary (6) 221 cases/1291 controls 5·91 (3·66-9·55) Fixed Q=7·51, P=0·19, I2=33·42 
HBsAg-individuals 
excluding Wu et al 170 Summary (5) 172 cases/769 controls 6·37 (3·74-10·86) Fixed Q=7·11, P=0·13,  I
2=43·71 
HBV only 
General population Summary (6) 5-8,57,170 244 cases/1072 controls 11·2 (7·48-16·7) Fixed Q=2·37, P=0·80,  I2=0·00 
General population after 
adjusted heterogeneity Summary (5) 
5-8,57 171 cases/638 controls 11·3 (6·75-18·9) Fixed Q=2·36, p=0·67,  I2=0·00 
Aflatoxin and 
HBV infection 
combined 
effects 
General population Summary (6) 5-8,57,170 554 cases/1456 controls 54·1 (21·3-137·7) Random Q=13·65, p=0·02,  I2=63·36 
General population after 
adjust heterogeneity Summary (5)
5-8,57 452 cases/847 controls 73·0 (36·0-148·3) Fixed Q=3·48, p=0·48,  I2=0·00 
                                                 
xi The summary odds ratio obtained from different follow-up studies for the Taiwan cohort was used to represent the effect of all studies in this cohorts, and 
combine with other studies 
Table 13 continued 
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4.2.6 MULTIPLICATIVE MODEL OF EFFECTS BETWEEN AFLATOXIN 
EXPOSURE AND CHRONIC HBV INFECTION 
The meta-analysis allowed us to quantitatively evaluate the model of effects between the 
two risk factors. The summary OR of six studies 5-8,57,170 reporting ORs of HCC risk from 
combination effects of aflatoxin exposure and HBV infection is 54.1 (21.3-137.7) with 
significant heterogeneity (Q=13.65, P=0.02, I2=63.36). The summary OR of the same batch of 
studies on HCC risk from aflatoxin exposure only is 5.91 (3.66-9.55), while the summary OR on 
HCC risk from chronic HBV infection only is 11.2 (7.48-16.7), both with no significant 
heterogeneity. If we excluded Wu et al 170 which contributes to the heterogeneity, the summary 
OR for combined effects increased to 73.0 (36.0-148.3), 6.37 (3.74-10.86) for aflatoxin exposure 
only and 11.3 (6.75-18.9) for chronic HBV infection only (Figure 7). These numbers indicated 
an almost perfect multiplicative model of effects between aflatoxin exposure and chronic HBV 
infection in inducing HCC risk.  
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A. Forest plot of combined ORs with 95% CI for association between liver cancer and chronic 
HBV+ only, excluding Wu et al 170; B. Forest plot of combined ORs with 95% CI for association 
between liver cancer and aflatoxin exposure only, excluding Wu et al 170; C. Forest plot of 
combined ORs with 95% CI for association between liver cancer and the combination effects of 
two risk factors, excluding Wu et al 170 
 
 
Figure 7. Forest plot of combined ORs for association between liver cancer and two 
risk factors 
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4.2.7 POPULATION ATTRIBUTABLE RISK OF HCC FROM AFLATOXIN 
EXPOSURE IN EACH STUDY POPULATION 
The PAR of aflatoxin-related HCC was calculated for each study population (Table 14). 
PAR is the proportion of the HCC cases that could be prevented by reducing aflatoxin exposures 
to “control” levels in each study. For example, HCC in the Chen et al 186 Taiwanese study 
population could be reduced by about 10% (2.5-12%) if dietary aflatoxin exposures in this 
population were reduced such that aflatoxin-albumin adduct levels were below 0.01 fmol/µg 
(detection limit in this study), or if dietary aflatoxin exposures could be decreased to below 4.3 
ng/kg bw/day (biomarker detection limit extrapolated to dietary exposure). HCC in the study 
population of Shanghai males in Qian et al. 6 could be reduced by about 9.0% (5.9-10.4%) if 
aflatoxin exposures in this population were reduced to below 6 ng/kg bw/day: the average 
aflatoxin exposure level in the control group. Our results showed that the PAR of HCC caused 
by aflatoxin is higher in HBV+ populations than in HBV- populations.  
In HBV+ populations in a Taiwanese cohort, the PAR for aflatoxin-related HCC is 
consistently decreasing, as indicated by a series of follow-up studies: 31% in 1980s 7, 12% in 
1990s 192, and 3% in 2000s 170. Overall, the PAR of aflatoxin-related HCC is decreasing in 
Taiwan in both HBV+ and HBV- individuals, from as high as 44% in 1990s 57 to 2% in 2000s170.  
The PAR of aflatoxin-induced liver cancer is changing over time, and varies by 
geographic regions; which may reflect differences in HBV prevalence, aflatoxin exposure across 
geographic regions, and changes in limits of detection. For example, the varying PAR estimates 
from six Chinese studies, Qian et al., Zhang et al., Sun et al, Huang et al, Long et al and 
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Szymanska et al 6,56,58,179,189,193 can be explained at least in part by these factors. These studies 
covered four different geographical areas of China: Shanghai, Henan, Qidong, and Guangxi.  
The Shanghai study indicated an 11% prevalence of detectable aflatoxin metabolites in urine 
samples, compared to 35% prevalence detected in the Guangxi study. This may reflect higher 
aflatoxin exposures in rural populations compared with the population of Shanghai. 
Correspondingly, the PAR of HCC from aflatoxin in Shanghai area is about 10%, while it is 
about 26% in Guangxi (Fusui area). In HBsAg+ individuals, the PAR of aflatoxin exposure for 
liver cancer risk is highest at 57% (16%-72%) in Qidong in Ming et al., 2002 193, where there are 
some of the highest aflatoxin exposures in China 172. In contrast, the PAR of aflatoxin-related 
HCC was nearly 0% as estimated from Szymanska et al 2009 58; possibly reflecting substantially 
reduced aflatoxin exposure from changing food patterns in the local population.  
In the 1990s, the PARs calculated from studies utilized urinary aflatoxin metabolites or 
albumin adducts (three studies) with fairly consistent results (6,7,195. The PAR is about 10% in the 
general study populations adjusted by HBV status, 30-40% in HBV+ populations, and less than 
5% in HBV- populations.  In the early 2000s, the PARs of HCC from aflatoxin ranged from 0 to 
63% in HBsAg+ groups, 2-20% in HBsAg- groups, and 2%-26% in general population.  In two 
sub-Saharan African countries, aflatoxin exposure could contribute up to more than 60% of 
population risk of liver cancer in HBsAg+ individuals, but less than 20% in HBsAg- individuals 
5,8,190,191.  
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Table 14. Population attributable risk of liver cancer caused by aflatoxin exposure in HBV+ populations, HBV- 
populations, and the general population 
Studies Exposure measurement 
PAR for aflatoxin 
attributable HCC risk in 
HBsAg+ 
PAR for aflatoxin 
attributable HCC risk in 
HBsAg- 
PAR for aflatoxin 
attributable HCC risk in 
general study population 
adjusted by HBsAg+ 
Qian et al., 1994 6 
(Shanghai, China) 
Multiple urinary 
aflatoxin metabolites 40% (24% - 47%)
1 3.6% (0.3% - 5.6%) 9.0% (5.9% -10.4%) 
Chen et al., 1996 186 
(Taiwan) AFB1 albumin adducts n/a n/a 10% (2.5% - 12%) 
Chen et al., 1996 187 
(Taiwan) 
AFB1 albumin adducts 
Low vs undetectable 
4.2% (0-13%) 
 
n/a 
HBV individuals only 
n/a 
HBV individuals only 
AFB1 albumin adducts 
High vs undetectable 4.5% (0-11%) 
n/a 
HBV individuals only 
n/a 
HBV individuals only 
 Sum = 8.7% (0-24%)  
n/a 
HBV individuals only 
n/a 
HBV individuals only 
Wang et al., 1996 7 
(Taiwan) 
AFB1 albumin adducts 31% (0-51%) 0 (0-2.3%) 5% (0-11%) 
Urinary aflatoxin 
metabolites 41% (8.1%-54%) 1% (0- 4.1%) 11% (1.4% - 13.7%) 
Lunn et al., 1997 57 
(Taiwan) AFB1-DNA adduct 31% (0-75%)
2 44% (29%-47%) n/a 
Yu et al., 1997188 
(Taiwan) 
1.61-2.85 ng/ml AFM1 
vs non-detectable) 2.1% (0%-7.2%) 
n/a 
HBV individuals only 
n/a 
HBV individuals only 
> 2.85 ng/ml AFM1 vs 
non-detectable) 
19% (2.2%-25%) 
 
n/a 
HBV individuals only 
n/a 
HBV individuals only 
 Sum = 21% (2.2% - 32%)  
n/a 
HBV individuals only 
n/a 
HBV individuals only 
Zhang et al., 1997 189 
(Henan, China) 
Corn consumption n/a n/a 17.5% (8%-18.4%) 
Peanut consumption n/a n/a 36% (16% - 45%) 
Kirk et al., 2000 190 
(The Gambia) Ser 249 TP53 mutation n/a n/a 17% (12%-18%) 
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Omer et al., 2001 191 
(Sudan) 
Average peanut butter 
consumption n/a n/a 23% (11%-29%) 
Sun et al., 2001 
(Taiwan) 192 AFB1 albumin adducts 12% (1.7% - 20%) 
n/a 
HBV individuals only 
n/a 
HBV individuals only 
Ming et al., 2002 193 
(Qidong, China) AFM1 57% (16%-72%)
3 n/a n/a 
Huang et al. 200356 
(Qidong, China) Ser 249 TP53 mutation n/a n/a 17% (13%-18%) 
Omer et al., 2004 
8(Sudan) 
Average peanut butter 
consumption 5.4% (0-62%)
4 20% (9.0%-25%) n/a 
Kirk et al., 2005 5 
(The Gambia) Ser 249 TP53 mutation 63% (39%-67%)
5 12% (6.3% -17%) 13% (12%-14%)6 
Wu et al., 2009 170 
(Taiwan) 
AFB1 albumin adducts 3.7% (0-11%) 1.7% (0-4.6%) 2.1% (0.06%-3.4%) 
urinary aflatoxin 
metabolites 3.1% (0-11.7%) 4.7% (1.2%-6.7%) 4.4% (1.6%-6.3%) 
Szymanska et al., 2009 
58 
(Qidong, China) 
AFB1 albumin adducts 0 (0-14%) 
n/a 
HBV individuals only 
n/a 
HBV individuals only 
Long et al., 2009179 
(Guangxi, China) 
AFB1-DNA adduct 
medium vs low n/a n/a 6.8% (4.5%-8.5%) 
AFB1-DNA adduct high 
vs low n/a n/a 19% (17%-20%) 
Total n/a n/a 26% (22%-29%) 
(1, 2, 4, 5 calculated from unadjusted ORs, 3 author estimated, 6 calculated from ORs unadjusted by HBsAg+) 
Table 14 continued 
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4.2.8 POPULATION ATTRIBUTABLE RISK FRACTION OF AFLATOXIN-
RELATED HCC IN COMBINED STUDIES 
We combined the total number of exposed cases, the total number of HBsAg+ or HBsAg- 
individuals, and the total number of controls from all the eligible studies to calculate the PAR of 
liver cancer from aflatoxin by using the combined ORs in: 1) the general population adjusted for 
HBV status, 2) HBV+ populations, and 3) HBV- populations. The results are presented in Tables 
15 and 16.  
We combined all aflatoxin-exposed cases, HBV+ and HBV- individuals, and controls 
from all eligible studies to calculate the PAR of aflatoxin-related HCC by HBsAg status and 
world region (Tables 15, 16).  The PAR of aflatoxin-related HCC in the general population after 
HBV adjustment is 17% (14-19%). Because the earlier sensitivity analysis demonstrated that the 
remaining studies after exclusion of Wu et al. 170 do not have statistically significant 
heterogeneity, we also calculated the PAR of aflatoxin-related HCC after exclusion of (30). The 
PAR increased to 23% (21-24%).  
The PAR of aflatoxin-related HCC in the HBV+ population is 21% (10-29%). A separate 
calculation was performed excluding Szymanska et al 58 and Wu et al 170, the most influential 
studies indicated by the sensitivity analysis. The new PAR of aflatoxin-related HCC in the 
HBV+ population was 25% (18-30%). The PAR of aflatoxin-related HCC in HBV- populations 
is 8.8% (6.7-10%).  
 In subgroup, the aflatoxin exposure is a more important risk factor of liver cancer in 
China and Sub-Saharan African countries, compared to it is in Taiwan. The aflatoxin was 
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estimated to attribute 25% (95%CI: 22%-27% of liver cancer cases in general population of 
China, and 19% (95% CI: 13%-22%) in Sub-Saharan Africa. In Taiwan, the number was 5.2% 
(2.9%-6.7%). 
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Table 15. Estimated population attributable HCC risk from aflatoxin exposure in the general population by combining 
the eligible studies 
Study population Total exposed 
cases (n1) 
Total sample 
size (n2) 
Pc 
(n1/n2) 
Summarized OR 
(95% CI) 
PAR (95% CI) 
General population 
adjusted by HBV status 
6,7,56,170,179,186,189-191 
China 475 1588 0.299 5.99 (3.70-9.69) 25% (22%-27%) 
Taiwan 113 1102 0.103 2.01 (1.40-2.89) 5.2% (2·9%-6.7%) 
Sub-Saharan 
Africa 
82 340 0.241 4.62 (2.12-10.08) 19% (13%-22%) 
Summary 670 3030 0.221 4·75 (2·78-8.11) 17% (14%-19%) 
General population 
adjusted by HBV status 
after excluding Wu et al. 
2009170 
Summary 583 2103 0.277 5.72(4.42-7.40) 23% (21%-24%) 
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Table 16. Estimated population attributable HCC risk from aflatoxin exposure in HBV+ and HBV- populations by 
combining the eligible studies 
Study population Total 
HBsAg+ 
(or 
HBsAg-) 
(n1) 
Total HCC 
cases in 
HBsAg+ (or 
HBsAg-) (n2) 
Total 
exposed 
HBsAg+ (or 
HBsAg-) 
(n3) 
Proportion of 
HCC cases in 
HBsAg+ (or 
HBsAg-) (W1) 
Proportion of 
exposed 
HBsAg+ (or 
HBsAg-) (P1) 
Summarized 
OR (95%CI) 
PAR (95% CI) 
HBV+ population 
5-
8,57,58,170,187,188,192,193 
China 457 189 276 0.414 0.604 2.00(0.84-4.75) 16% (0-29%) 
Taiwan  564 254 314 0.450 0.557 1.81(1.29-2.56) 14% (6.3%-21%) 
Sub-
Saharan 
Africa 
184 128 76 0.696 0.413 6.48(0.22-194) 48% (0-69%) 
Summaryxii 1205 571 666 0.473 0.553 2.39 (1.50-3.82) 21% (10%-29%) 
HBV+ population 
after excluding 
Szymanska et al. 
200958 and Wu et 
al170 
China 208 63 108 0.303 0.519 3.01 (1.86-4.88) 16% (9%-20%) 
Taiwan 368 186 216 0.505 0.587 2.59 (1.63-4.13) 24% (14%-33%) 
Summary 760 377 400 0.496 0.526 2.90 (2.09-4.01) 25% (18%-30%) 
HBV- population 
5-8,57,170 
Taiwan 745 81 332 0.109 0.446 5.00 (2.22-
11.28) 
7% (3.8%-8·9%) 
Sub-
Saharan 
Africa 
513 122 113 0.238 0.220 8.40 (4.15 -
16.99) 
15% (9.7% -
19%) 
Summary 1632 227 617 0.139 0.353 5.91 (3.66-9.55) 8.8% (6.7%-
10%) 
 
 
 
                                                 
xii Studies (including two studies in Sub-Saharan Africa countries) with unadjusted ORs were also combined to calculate the overall PAR, thus the Sub-Saharan 
study population can be included. 
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Figure 8. Funnel plot to assess possible publication or other selection bias for the association between aflatoxin 
exposure and liver cancer risk in general population. 
 
No statistically significant asymmetry was found. Each circle represents 1 study. 10 studies 6,7,56,57,170,179,186,189-191 are eligible for this 
plot. 7 studies not included (5 only studied the association in HBsAg+ individuals, and 2 are duplicate studies included in meta-
analysis for different data extraction purpose, as explained in the Methods section). 
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4.3 DISCUSSION 
Aflatoxin exposure is significantly associated with HCC risk regardless of HBV status. 
Our meta-analyses show that in areas of high aflatoxin exposure and chronic HBV infection, 
aflatoxin exposure and HBV have a nearly perfectly multiplicative relationship in increasing 
HCC risk.  In populations including both HBV+ and HBV- individuals in the geographic regions 
studied, the PAR of aflatoxin-related HCC was estimated at 17% (14-19%). This implies that if it 
were possible to reduce aflatoxin to below detectable limits in these regions, HCC incidence 
could be reduced by 14-19%. There are roughly 520,000 new HCC cases in China, southeastern 
Asia and sub-Saharan Africa each year 34. If the PARs are generalized to these areas, the 
implication is that, by reducing aflatoxin in humans diets to below detectable levels, 72,800 to 
98,800 new HCC cases could be prevented every year. If this PAR were generalized to regions 
of the world beyond Africa and Asia, the overall number of HCC cases (749,000 new cases per 
year (32)) that could be prevented by aflatoxin control would reach 105,000-142,000. 
The PAR of aflatoxin-related HCC increases to 23% (21-24%), and heterogeneity 
amongst the studies decreases significantly, if one study 170 is excluded from the meta-analysis.  
However, this study is important because it suggests that aflatoxin exposure is decreasing over 
time in the Taiwanese (Penghu) population studied. Our PAR estimates for individual studies 
showed a decrease in PAR of aflatoxin-related HCC in the Penghu cohort in the last three 
decades.  It is worth noting that in a 1970s food survey, over one-third of peanuts in Penghu were 
heavily contaminated by aflatoxins, with an average aflatoxin content of 167 µg/kg 196. Mean 
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urinary aflatoxin in HCC patients in this cohort from was 219 µg/ml in 1991/1992 7,186, and 
decreased to 0.017 µg/ml in HCC patients in the same cohort in 2004 170. Also, the HBV 
vaccination program in Taiwan has successfully reduced HBV prevalence, further reducing HCC 
risk 197.  
In some parts of the world such as Taiwan, aflatoxin exposure is decreasing. In other 
parts of the world such as Africa, rural China, and Southeast Asia, there is little evidence that 
aflatoxin exposure is decreasing; in fact, two recent Kenyan events of extremely high aflatoxin 
levels in maize (in 2004-2005, and again in 2010) suggest the opposite. With climate change, 
aflatoxin contamination in food crops may become exacerbated due to conditions favoring 
proliferation of Aspergilli (35). Hence, further efforts to reduce aflatoxin-related disease are 
needed in high-risk areas of the world. 
Aflatoxin exposure can be measured by dietary questionnaires, direct measurements in 
foodstuffs, or biomarkers. In the early years of investigating the association between aflatoxin 
and HCC development, measurement of aflatoxin exposure had several limitations. Dietary 
questionnaires are inadequate to measure the aflatoxin intake because the content of aflatoxin in 
individual foods, or even individual kernels of foods, can vary widely 198; and recall bias of 
subject participants may further reduce accuracy of questionnaire methods.  
In more recent studies, biomarkers of aflatoxin exposure and effect have become useful 
for more accurately determine the relevant exposures to aflatoxin that result in human disease.  
The biomarkers AFB1-N7-guanine, AFB1-albumin adduct, AFB1-DNA adducts, and the 
TP53 249ser mutations are all biomarkers of biological effects of aflatoxin 17. Therefore, the Pc 
which is calculated as prevalence of aflatoxin exposure in population should be more properly 
interpreted as the prevalence of biological effects that are caused by aflatoxin in the study 
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population. This is not always directly correlated with actual aflatoxin exposure in the diet, due 
to individual differences in aflatoxin metabolism. 
There are several limitations in this analysis. First, the epidemiological studies included 
were conducted in areas of the world with both high aflatoxin and HBV (Asia and sub-Saharan 
Africa).  Thus, although these regions account for most of the aflatoxin-induced HCC cases 
worldwide (13), the estimated PAR is not necessarily applicable in areas with much lower 
aflatoxin exposures. Second, odds ratios from studies employing food surveys, exposure 
biomarkers and biological effect biomarkers were combined. This decreases the precision of the 
analysis, as different biomarkers have different detection limits and measure different endpoints, 
and food surveys are less precise than biomarkers for exposure estimation.  Third, the PAR is 
meant to represent the proportion by which disease could be reduced if the risk factor in question 
were removed. It is not possible to instantaneously reduce aflatoxin to below detectable limits 
worldwide – rather, the PAR calculated is meant to estimate the burden of HCC caused by one 
risk factor (aflatoxin), and to project the extent to which the problem could be reduced in future 
generations if aflatoxin control strategies were widespread.  
In summary, this study is the first to quantitatively evaluate the model of effects between 
aflatoxin and HBV in inducing liver cancer by combining results from multiple epidemiological 
studies. The range of PARs calculated in this analysis, 14-19% (21-24% excluding one study 
contributing to heterogeneity), is consistent with our previous report of 5-28% using a different 
methodology (quantitative cancer risk assessment) 180. The PAR of aflatoxin-related HCC is 
higher in HBsAg+ populations than HBsAg- populations. In recent years, the PAR of aflatoxin-
related HCC has shown a decreasing trend in areas such as Taiwan, indicating the benefits of 
reduced aflatoxin exposure and HBV prevalence by public health interventions. 
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5.0  CONCLUSIONS AND PUBLIC HEALTH SIGNIFICANCE  
We adopted two methods to estimate the aflatoxin-attributable liver cancer risk in 
multiple countries/regions: 1) A risk assessment relying on food consumption and food 
contamination data to measure the exposure, and 2) a meta-analysis to pool the ORs from studies 
mainly relying on biomarker data to quantify the association. The overall range of PARs 
calculated from the two methods, 21-24% by meta-analysis excluding one study contributing to 
heterogeneity, and  5-28% using a quantitative cancer risk assessment180, are consistent with 
each other (Table 17). They both presented a higher PAR in HBsAg+ individuals than in 
HBsAg- individuals. But the PAR calculated from the meta- analysis particularly reflected the 
disease burden in areas with high aflatoxin exposure, because the meta-analysis was dependent 
on the studies in these areas – China, Taiwan and Sub-Saharan Africa.  Also, the estimates 
calculated by employing the meta-analysis has much narrower ranges compared to the ones from 
risk assessment, indicated the reduced uncertainties in exposure assessment, the dose-response 
relationship and the model of interaction effects between two risk factors (aflatoxin exposure and 
chronic HBV).  
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Table 17. Comparing PARs of liver cancer from aflatoxin exposure calculated by 
two methods 
 Estimates from risk assessment model 
(Global burden) 
Estimates from meta-analysis 
(Burden of areas with high aflatoxin exposure) 
HBsAg- 5%-26% 8.8% (6.7% - 10%) 
HBsAg+ 11%-74% 25% (18%-30%) 
Overall 5%-28% 23% (21%-24%) 
 
While two analysis methods both aimed to address a significant public health question, 
each method has its own advantages and limitations. The wide range of risk estimates computed 
from risk assessment reflects the limitations in determining levels of aflatoxin exposure solely by 
food consumption and aflatoxin contamination data; however, food studies were best available 
data and easy-to-obtain sources, to help determining and communicating risk in vast majority of 
the countries of the world, and thus possible to conduct a disease burden assessment at global 
level. The assumptions of a uniformly multiplicative model of combined effects, and the 
incomplete data on the chronic HBV infection prevalence in different regions, also hindered the 
accuracy when the risk assessment results were extrapolated to specific countries or regions. 
From this point of view, the location-specific rates were employed to get the estimates for 
particular geographic areas.  
Compared to risk assessment which relies on food data to measure aflatoxin exposure, the 
quantification of association between exposure and liver cancer risk is very much improved by 
pooling the ORs from studies using biomarker data to measure the exposure. The systematic 
approach is also helpful to get rid of random error and give reliable estimates on the strength of 
the association. However, there is limited number of eligible studies with accessible data. The 
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current meta-analysis is based upon studies from China, Taiwan, and two Sub-Saharan African 
countries. In addition, the meta-analysis is hindered by the heterogeneity and quality of studies. 
This study answered an important public health question - the global burden of aflatoxin-
attributable liver cancer cases. From our analysis, Aflatoxin may play a causative role in 4.6-
28.2% of all global HCC cases. 25,200-155,000 HCC cases worldwide may be attributable to 
aflatoxin exposure. Most cases occur in sub-Saharan Africa, Southeast Asia, and China, where 
populations suffer from both high HBV prevalence and largely uncontrolled dietary aflatoxin. In 
these areas, the PAR of aflatoxin-related HCC is 23% (21-24%) overall, and is higher in HBV+ 
individuals (18-30%) than in HBV- individuals (6.7%-10%). After adjustment for heterogeneity, 
the combined OR of HCC from combination effects of aflatoxin and HBV+ is 73.0 (36.0-148.3), 
11.3 (6.75-18.9) from HBV+ only and 6.37 (3.74-10.86) from aflatoxin exposure only, indicating 
an almost perfectly multiplicative model of effects between aflatoxin exposure and HBV+. HBV 
vaccination should be a very effective intervention strategy to reduce the cancer burden 
attributable to aflatoxin, and has demonstrated the impressive benefit, both in Fusui County, 
China and Taiwan.  
Overall, the risk assessment model and meta-analysis are both useful tools to estimate the 
general HCC burden attributable to aflatoxin exposure. Together they not only help to provide 
policy makers and scientists straightforward information for risk communication and decision 
making, but also are marked as translational toxicological efforts from molecular mechanisms to 
global public health.  
 
 
93 
 
ABBREVIATIONS 
A. flavus  = Aspergillus flavus 
A. parasiticus = Aspergillus parasiticus 
AFB1   = aflatoxin B1 
AFM1      = Aflatoxin M1 
FAO  = Food and Agriculture Organization 
FDA  = United States Food and Drug Administration 
GEMS  = Global Environment Monitoring System 
HBsAg   = Hepatitis B virus surface antigen 
HBV   = hepatitis B virus 
HCC   = hepatocellular carcinoma 
HCV       = Hepatitis C virus 
IARC     = International Agency for Research on Cancer 
JECFA = Joint Food and Agriculture Organization / World Health Organization    
Expert Committee on Food Additives 
OR         = Odds ratio 
PAR        = Population attributable risk  
RR          = Relative risk 
WHO  = World Health Organization 
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